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The O-linked-N-acetylglucosamine (O-GlcNAc) post translational modification 
emerged as an important cue in controlling key cell mechanisms. This thesis 
aimed to investigate the role and significance of O-GlcNAc in human 
pluripotent stem cells (hPSC).  
We first started by demonstrating the importance of O-GlcNAc for hPSC 
phenotype and first revealed that O-GlcNAc excess had no significant effect 
on pluripotency. However, excess of O-GlcNAc altered specific differentiation 
lineages: adipose markers expressions were increased and ectoderm 
markers expressions were decreased in differentiating hPSC (Maury et al., 
2013). 
Additionally, we also investigated the potential of Multiple Reaction Monitoring 
Mass Spectrometry (MRM-MS) to facilitate rapid discovery and quantification 
of native O-GlcNAcylated peptides and proteins (Maury et al., 2014). In this 
study, we showed that MRM-MS was able to detect and robustly quantify a 
standard O-GlcNAc peptide. Then, we applied this MRM-MS approach to 
hESC proteins and discovered a novel GSK-3β O-GlcNAcylated peptide 
bearing 3 potential O-GlcNAcylation sites.  
As our first set of data suggested that some human embryonic stem cells 
(hESC) differentiation pathways were regulated by O-GlcNAcylated proteins, 
we attempted to identify hESC O-GlcNAcylated proteins. Accordingly, 
following an O-GlcNAc enrichment step, we identified 235 hESC O-
GlcNAcylated proteins by MS. Interestingly, most of our highest hits proteins 
were involved in regulating stem cell properties. Consequently, we decided to 
focus our study on RING2, a polycomb protein catalysing the ubiquitinylation 
x 
 
of histone H2A to repress gene expression. We proved that RING2 was 
bearing O-GlcNAc in hESC. By using MRM-MS and additional 
methodologies, we mapped the O-GlcNAcylated sites on RING2 at T250/S251. 
We then demonstrated that O-GlcNAcylation was modulating RING2 protein-
protein interaction towards CBX7 and RYBP. Indeed, O-GlcNAc excess 
increased CBX7-RING2 affinity and decreased RYBP-RING2 affinity. RYBP 
and CBX7 are known to direct RING2 repression towards gene subsets which 
are mainly exclusive for either RYBP or CBX7. In conclusion, these data 
suggest that by regulating RING2 protein-protein interaction, O-GlcNAc might 
direct RING2 repression towards specific gene subsets in hESC.    
To the best of our knowledge, this is the first report demonstrating O-GlcNAc 
involvement in hESC differentiation and showing that O-GlcNAc modifies 
RING2 and regulates RING2 protein-protein interaction. Finally, our data 
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CHAPTER 1 – INTRODUCTION 
 
1.1 Background  
 
O-linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification 
of nucleocytoplasmic proteins (Torres and Hart, 1984). O-GlcNAc is added on 
serine and threonine residues by an O-GlcNAc transferase (OGT) and is 
removed by an O-GlcNAc hydrolase (OGA) (Haltiwanger et al., 1990), (Dong 
and Hart, 1994) (Figure 1-1). Even though O-GlcNAc studies remains 
challenging due to the difficulties in detecting the modification (Hart and 
Akimoto, 2009); several reports have revealed the importance of O-GlcNAc in 
modifying and regulating proteins involved in various cellular processes 
(transcription, nutriment sensing and stress response) and diseases 
(diabetes, Alzheimer’s disease and cancers) as shown in Figure 1-1 (Ozcan 
et al., 2010). A few studies have also shed light on the involvement of O-
GlcNAc in murine development. For instance, OGT knock-out was reported 
as embryonic lethal in mice (Shafi et al., 2000); and a global increase in O-
GlcNAcylation level was shown to enhance pluripotency in mouse embryonic 
stem cells (mESC) (Jang et al., 2012). However, no study has yet been 




Figure 1-1 O-linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification 
of nucleocytoplasmic proteins. 
O-GlcNAc is reversibly added onto serine and threonine residues of nucleocytoplasmic 
proteins. O-GlcNAc modified proteins are involved in various cellular processes and diseases. 
Figure modified from (Hart et al., 2007) and (Hart and Akimoto, 2009). 
 
Human pluripotent stem cells (hPSC), comprises of both human embryonic 
stem cells (hESC) (Thomson et al., 1998) and induced pluripotent stem cells 
(iPSC) (Takahashi and Yamanaka, 2006). hESC are isolated from the inner 
cell mass of blastocysts (Thomson et al., 1998); whereas iPSC are usually 
created by reprogramming differentiated cells via the expression of four 
transcription factors (OCT3/4, SOX2, c-MYC, and KLF4) (Takahashi and 
Yamanaka, 2006) (Figure 1-2). hPSC have three main phenotype: proliferate 
ad infinitum, differentiate into cells of the three germ layers (endo-, ecto-, and 
meso-derm) and form teratomas when transplanted into immunosuppressed 
mice (Thomson et al., 1998), (Takahashi and Yamanaka, 2006). Owing to 
these unique properties, hPSC hold great promise for cell transplantation, 
basic/translational research and biotechnology (Grabel et al., 2012). 
Examples of potential applications of hPSC are outlined in Figure 1-2. 
OGT
OGA  







However, before hPSC can be clinically relevant, cues controlling 
pluripotency and differentiation need to be clearly understood. Those cues 
are diverse (Bratt-Leal et al., 2009) and include soluble factors, extracellular 
matrix-cell interactions, cell-cell interactions, and intracellular signals such as 
phosphorylation (Van Hoof et al., 2009) and glycosylation (Cheray et al., 
2011). Even though surface N-glycans have been shown to play an active 
role in the maintenance of undifferentiated stem cells (Yagi et al., 2012), the 
contribution of O-linked N-acetylglucosamine (O-GlcNAc) modification to 
hPSC properties remains largely unknown.    
 
Figure 1-2 Origins and uses of human pluripotent stem cells (hPSC)  
Human embryonic stem cells (hESC) are isolated from the inner cell mass of blastocysts. 
Human induced pluripotent stem cells (iPSC) can be created by viral transduction or non-viral 
transfection of human fibroblasts. Human pluripotent stem cells (hPSC) are maintained in 
culture and can be used to study mechanisms of pluripotency. hPSC can also be triggered into 
differentiation to study mechanisms of human development. Differentiated hPSC have many 









Cultured human pluripotent stem cells (hPSC)
4 
 
Figure modified from https://research.cchmc.org/stemcell/what-can-i-do and 
http://www.tc.umn.edu/~kaufm020/research.htm both accessed the 01-Nov-2013. 
 
1.2 Thesis motivations and objectives 
 
In this context, our first motivation lied in the lack of knowledge regarding O-
GlcNAc function on hPSC phenotype. Even though the function of O-GlcNAc 
on mESC phenotype has started to be unravelled in a few reports (as 
mentioned above (Shafi et al., 2000), (Jang et al., 2012)), it may be different 
for hPSC because mESC and hPSC are well known to differ in pluripotency 
maintenance requirements (Ginis et al., 2004) and differentiation potential 
(Douglas et al., 2009). Furthermore, deciphering O-GlcNAc function for hPSC 
properties might have a significant impact on basic/translational research and 
applied science.  
We here hypothesized that O-GlcNAcylated proteins are involved in 
regulating hPSC properties. We therefore started by determining the global 
effect of O-GlcNAc excess on hPSC pluripotency maintenance and 
differentiation. In contrast to mESC, O-GlcNAc excess was shown to affect 
hPSC differentiation specifically towards ectoderm and adipose lineages. We 
then identify hESC O-GlcNAcylated proteins. Among the identified proteins, 
we specifically selected RING2 to carry out a functional study as RING2 is an 
epigenetic repressor essential for proper development and cell differentiation 
in mammals (Surface et al., 2010). We also localized RING2 O-GlcNAcylation 
sites in a region of RING2 which is known to control protein-protein interaction 
(Bezsonova et al., 2009), (Wang et al., 2010a). Subsequently, we 
demonstrated that O-GlcNAc excess increased RING2-CBX7 affinity and 
decreased RING2-RYBP affinity. Finally, we hypothesized that RING2 O-
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GlcNAcylation might be used to regulate which RING2-targeted genes are 
being repressed.  
 
Our second motivation lied in the lack of fast and straightforward mass 
spectrometry (MS) methodology to detect and quantify small amount of native 
O-GlcNAcylated peptides. As mentioned above, O-GlcNAc detection remains 
challenging due to the low stoichiometry of the modification (Dong et al., 
1993). Therefore, labeling and enrichment techniques are usually needed to 
detect O-GlcNAcylated peptides by shotgun MS (Zachara et al., 2011). In 
contrast to shotgun MS, a targeted MS approach would be beneficial when 
working on a pre-selected protein of interest. Indeed, a targeted MS approach 
might require less enrichment and labeling steps making sample preparation 
faster and easier. Also such a targeted MS method might be able to directly 
quantify the amount of native O-GlcNAc peptide whereas shotgun MS 
requires peptide labeling for quantification (Khidekel and Hsieh-Wilson, 2007), 
(Wang et al., 2009). 
We here hypothesized that current MS methods can be improved to facilitate 
O-GlcNAc peptide detection. We made use of a targeted MS method, the 
Multiple Reaction Monitoring MS (MRM-MS), for the study of native O-
GlcNAcylated proteins. We first performed MRM-MS detection and 
quantification on a commercially available O-GlcNAcylated peptide as a proof 
of concept. This optimized MRM-MS approach was then applied to discover 
novel hESC O-GlcNAcylated peptides.  
 
Overall, this thesis has two main outcomes: a functional study outcome 
reporting the role of O-GlcNAc in hPSC; and a technology development 
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outcome establishing MRM-MS as a fast and straightforward MS method to 
study native O-GlcNAcylated proteins.   
 
1.3 Thesis organization 
 
This thesis is organized into seven chapters: 
CHAPTER 1 presents the thesis background, motivation and objectives. 
CHAPTER 2 consists of a literature review focusing especially on O-
GlcNAcylation and polycomb proteins.  
CHAPTER 3 describes the materials and methods used to perform the 
experiments reported in this thesis. 
CHAPTER 4 investigates the importance of global O-GlcNAcylation on hPSC 
phenotype. This chapter reveals that an excess of O-GlcNAcylation 
modulates hPSC differentiation towards the ectoderm and adipose lineages.   
CHAPTER 5 focuses on the development of MRM-MS for O-GlcNAc analysis. 
This chapter demonstrates the application of MRM-MS for the discovery and 
quantification of native O-GlcNAcylated proteins without any need for 
extensive enrichments.   
CHAPTER 6 reports the functional sudy of O-GlcNAc on an essential hESC 
differentiation modulator: RING2. The chapter first identifies 235 O-
GlcNAcylated proteins in hESC. Then, a functional study focused on RING2 
reveals RING2 O-GlcNAcylation sites. The chapter demonstrates that O-
GlcNAcylation regulates RING2 protein-protein interaction with CBX7 and 
RYBP and allows us to hypothesize that RING2 O-GlcNAcylation might be 
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used as a switch to regulate which RING2-targeted genes are being 
repressed.  
CHAPTER 7 concludes the thesis by summarizing each important finding and 
provides recommendations for future research aiming to pursue the thesis 
research.   




CHAPTER 2 - LITERATURE REVIEW 
 
2.1 O-GlcNAc discovery and overview 
 
The existence of O-GlcNAc was first reported by Carmen Torres and Gerald 
Hart in 1984 (Torres and Hart, 1984). Indeed, while aiming to identify 
lymphocyte cell-surface oligosaccharides, the authors detected the presence 
of O-GlcNAc monosaccharide present not only on membrane proteins but 
also on cytoplasmic proteins. This serendipitous discovery went against the 
dogma that glycoproteins are only present on cell membranes. Following this 
discovery, many reports have since been published elucidating the 
significance and regulation of this specific modification.  
 
Figure 2-1 O-GlcNAc addition and removal on nucleocytoplasmic proteins. 
 
Briefly, O-GlcNAc is present in viruses and most eukaryotic multi-organisms 
such as fungi, plants and animals (Hart and Akimoto, 2009). O-GlcNAc is a 
post-translational modification added to specific serine and threonine residues 
of nucleocytoplasmic proteins by the action of a glycosyltransferase called O-
GlcNAc transferase (OGT) (Haltiwanger et al., 1990), (Haltiwanger et al., 
















an O-GlcNAc hydrolase (OGA) (Dong and Hart, 1994) (Figure 2-1). This 
reversible and dynamic modification has been shown to regulate different 
cellular processes such as protein-protein interaction, protein-DNA 
interaction, nucleocytoplasmic shuttling and protein stability (Ozcan et al., 
2010). Interestingly, O-GlcNAc regulation interplays with phosphorylation 
through competition and cooperation mechanisms (Zeidan and Hart, 2010). 
To date, thousands nucleocytoplasmic proteins have been reported as O-
GlcNAc modified (Hart and Akimoto, 2009), (Trinidad et al., 2012). Those O-
GlcNAcylated proteins are involved in a variety of cellular processes such as 
apoptosis, stress response, cell cycle, gene transcription and development. In 
addition, O-GlcNAc deregulation has been shown to participate in the etiology 
of several diseases such as cancers, diabetes, cardiovascular diseases and 
Alzheimer’s disease. Overall, O-GlcNAc is considered to be one of the most 
abundant post-translational modifications and its study have a significant 
impact on numerous biological fields (Hart and Akimoto, 2009).  
 
2.2 O-GlcNAc addition and removal 
 
O-GlcNAc is the end product of the hexosamine biosynthesis pathway (HBP) 
starting from intracellular glucose (Figure 2-2) which is processed through 
HBP by 6 enzymatic reactions producing intermediates alternatively used in 
parallel pathways (e.g. fructose-6-phosphate is used to produce ATP and 
NADH through glycolysis). Eventually a small proportion of intercellular 
glucose (2-5%) is transformed into uridine diphosphate N-acetylglucosamine 
(UDP-GlcNAc) (Butkinaree et al., 2010). Because HBP starts from glucose, 
O-GlcNAc is often presented as a cell sensor for glucose availability and has 
been linked to nutritional diseases such as diabetes (Zagorski and Hart, 
2010). HBP is linked to almost all cellular metabolic pathways (Sanoyo-
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Ramos et al., 2012). Indeed, through the conversion steps from glucose to 
UDP-GlcNAc, HBP is linked to the metabolisms of amino acids, fatty acids, 
and nucleotides as well as ATP synthesis. HBP is also linked to the synthesis 
of glycosaminoglycans, proteoglycans, glycoproteins and glycolipids through 
the formation of UDP-GlcNAc.  
 
Figure 2-2 Hexosamine biosynthesis pathway (HBP). 
Figure modified from (Butkinaree et al., 2010).  
 
At the end of the HBP pathway, UDP-GlcNAc is used by OGT for the 
enzymatical addition of O-GlcNAc on serine and threonine residues of 
nucleocytoplasmic proteins (Haltiwanger et al., 1990), (Haltiwanger et al., 
1992). In mammals, the OGT gene encoding for this transferase is located on 
the X chromosome and codes for three splicing variants: ncOGT, mOGT and 
sOGT (Shafi et al., 2000). These three splicing variants differ in their number 
of tetracopeptide repeats (TPRs) units and cellular location as illustrated in 
Figure 2-3 (Vocadlo, 2012). The mitochondrial OGT named mOGT, was 





mOGT remains poorly studied. The nucleocytoplasmic OGTs, namely, 
ncOGT and sOGT, can exist under different forms either as ncOGT 
homodimer (Jinek et al., 2004) or hetero-trimer composed of 2 ncOGT and 1 
sOGT (Haltiwanger et al., 1992). Substrate recognition of OGT is not fully 
understood. OGT was shown to bind to its substrate through its TPR domain 
(Lyer and Hart, 2003). Several other studies have also shown that OGT 
substrate specificity is regulated through OGT-interacting proteins (Yang et 
al., 2002), (Cheung et al., 2008). Quite a number of OGT-interacting proteins 
have been reported so far (e.g. MYPT1, CARM1 and THAP1) (Cheung et al., 
2008), (Mazars et al., 2010); suggesting that OGT is associated with a variety 
of protein complexes each having their own substrate subset. Interestingly, 
OGT was shown to be modified and regulated by phosphorylation (Whelan et 
al., 2008) as well as auto-glycosylated by O-GlcNAc (Lubas and Hanover, 
2000). 
 
Figure 2-3 Presentation of the domains, structures and locations of the different OGT 
variants. 
Figure modified from (Vocadlo, 2012). 
  
Even though no consensus sequence of O-GlcNAcylation site has been 
clearly established so far, the modification sites seem to usually be located 


























GlcNAc sites in Figure 2-4 (Chalkley et al., 2009). Since prolines are often 
found on protein turns (Lodish et al., 2000), this representative sequence 
suggest that O-GlcNAc modifications are located on the exposed surface of 
protein structure. 
 
Figure 2-4 Representative sequence surrounding O-GlcNAcylated serine and threonine 
residues (at location 0) combining 58 identified O-GlcNAcylation sites. 
Figure from (Chalkley et al., 2009). 
 
 
Once bound to a protein backbone, O-GlcNAc can be removed enzymatically 
by OGA (Dong and Hart, 1994). In mammals, there is only one gene, 
Meningioma Expressed Antigen 5 (MGEA5), encoding two OGA splicing 
variants: OGA-L and OGA-S. Those splicing variants differ in size, number of 
domains, structures and locations (Figure 2-5) (Vocadlo, 2012). Substrate 
recognition by OGA is not fully understood, however reports have suggested 
that the recognition might involve an OGA peptide binding groove domain 
located from the 176th to the 289th amino acid residues (Schimpl et al., 2010). 
Other studies have also underlined the importance of substrate structure and 
more specifically the importance of sugar accessibility within the glycoprotein 
(Shen et al., 2012). In addition, OGA was shown to be modified and 
potentially regulated itself by O-GlcNAc (Lazarus et al., 2006) and 




Figure 2-5 Presentation of the domains, structures and locations of the different OGA 
variants. 
Figure modified from (Vocadlo, 2012). 
 
Overall, O-GlcNAc is a reversible and dynamic modification whose 
addition/removal rate is faster than protein backbone turnover rate (Chou et 
al., 1992). In addition, O-GlcNAc addition/removal is regulated by a complex 
interplay of factors from cellular environment (glucose availability, metabolic 
pathways) and factors related to O-GlcNAc enzymes (enzyme/susbtrate 
structure, OGT/OGA-interacting proteins, post-translational modifications).  
 
2.3 O-GlcNAcylation and ‘classical glycosylation’  
 
O-GlcNAc is a monosaccharide and is therefore defined as a post-
translational modification similar to ‘classical’ glycans (O- and N-glycans). 
However O-GlcNAcylation differ from  ‘classical’ glycosylation in many 
characteristics (as summarized in Figure 2-6) (Hart and Akimoto, 2009). First, 
O-GlcNAc is a monosaccharide whereas ‘classical’ glycans are poly-
saccharide. Also O-GlcNAc addition/removal is quite simple (O-GlcNAcylation 
occurs in the cytoplasm and only involves 2 enzymes) whereas ‘classical’ 

















and involves many transferases and hydrolases). Then O-GlcNAcylated 
proteins are mainly found in the cytoplasm and nucleus whereas ‘classical’ 
glycosylated proteins are usually located on the cell membrane. Finally, O-
GlcNAc regulates protein function (protein-protein interaction, protein-DNA 
interaction, nucleocytoplasmic shuttling and protein stability); whereas 
‘classical’ glycosylation is mainly involved in regulating cell signalling. To 
summarize, even though O-GlcNAc is chemically a glycosylation, O-GlcNAc 
is very dissimilar to ‘classical’ glycosylation. 
 
Figure 2-6 Comparison of O-GlcNAcylation with ‘classical’ glycosylations (O-, N-
glycosylation) and with phosphorylation. 
 
Interestingly, and as presented in the following paragraph, O-GlcNAcylation 
shares many characteristics with another well-known post-translational 
modification: phosphorylation.   
 
2.4 O-GlcNAc / phosphorylation interplay 
 
O-GlcNAc is often presented as analogue to phosphorylation (Hart and 
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dynamic, and appear on particular serine and threonine residues of 
nucleocytoplasmic proteins. Not surprisingly, O-GlcNAc has been shown to 
interplay with phosphorylation. The two modifications can compete for either 
the same site (i.e. c-Myc (Kamemura et al., 2002)) or adjacent sites (i.e. RNA 
polymerase II (Kelly et al., 1993)) (Figure 2-6 A, B). Alternatively to 
competition, the two modifications can also cooperate to modify adjacent sites 
(Figure 2-6 C). In such cooperation mechanisms, the addition of O-GlcNAc 
might be facilitated by the presence of an adjacent phosphorylation like it has 
been reported for prohibitin (Ande et al., 2009). The authors suggested that 
O-GlcNAcylation of prohibitin might here facilitate the recruitment of kinases.   
 
Figure 2-7 Interplay between O-GlcNAcylation and Phosphorylation. 
Figure modified from (Butkinaree et al., 2010). Illustration of the three O-GlcNAc / 
phosphorylation interplay A. same site competition, B. adjacent site competition, C. 
cooperation through adjacent site occupancy.  
 
 
To date, most of the identified O-GlcNAcylated proteins are also found to be 
phosphorylated (Kamemura and Hart, 2003). Furthermore, O-GlcNAcylation / 
phosphorylation interplay go beyond enzymes’ substrate as quite a number of 
kinases itself have been shown to be modified and regulated by O-GlcNAc 





known to be phosphorylated (Whelan et al., 2008), (Butkinaree et al., 2010). 
Those reports thus suggest that O-GlcNAc enzymes and phosphoenzymes 
regulate each other’s activity to fine tune O-GlcNAcylation and 
phosphorylation at cellular level.   
 
2.5 O-GlcNAc biological function 
 
Mechanistically, O-GlcNAc controls protein function by regulating protein-
protein interaction (Lim and Chang), protein-DNA interaction (Shaw et al., 
1996), nucleocytoplasmic shuttling (Andrali et al., 2007) and protein stability 
(Chen et al., 2006) (see Figure 2-7 for examples). Interestingly, such 
regulation is sometimes reported as involving O-GlcNAc interplay with other 
post-translational modifications such as ubiquitinylation (Guinez et al., 2008) 
and phosphorylation (see above paragraph 2.3 O-GlcNAc / phosphorylation 
interplay). As a consequence some proteins can exist under various 
modification states (e.g. naked; phosphorylated; O-GlcNAcylated; and 
simultaneoulsy O-GlcNAcylated and phosphorylated) each variant resulting 
into a specific function for the modified protein (Ande et al., 2009), (Ozcan et 
al., 2010).    
 
Figure 2-8 Examples of O-GlcNAc regulation. 
Figure modified from (Ozcan et al., 2010). A. In high glucose environment, OGT O-
GlcNAcylates YY1. YY1 O-GlcNAcylation disrupts YY1 association with Rb. This enables YY1 




gene expression. B. O-GlcNAcylation of Pdx-1 increases Pdx-1 binding to DNA. O-
GlcNAcylation of NeuoD1 triggers the protein translocation from the cytoplasm to nucleus and 
allows NeuroD1 to bind to DNA. The synergistic binding of Pdx-1, NeuroD1 and MafA to DNA 
activates INS (insulin) gene expression.   
 
As mentioned earlier, more than 1000 proteins have been reported as O-
GlcNAcylated (Hart and Akimoto, 2009), (Trinidad et al., 2012); however the 
actual number of O-GlcNAcylated proteins is probably a lot higher. 
Furthermore, because most of the reported O-GlcNAcylated proteins are also 
known to be phosphorylated (Kamemura and Hart, 2003); some have 
suggested that O-GlcNAcylated proteins might be as abundant as 
phosphorylated proteins (Hart et al., 1996).  
Because of the importance of proteins modified by O-GlcNAc, O-GlcNAc has 
been linked to numerous cell mechanisms (Table 2-1) and diseases (Table 
2-2). Overall, the study of O-GlcNAc is relevant for many biological fields and 
biological questions; however the characterization of O-GlcNAc proteins 






















Examples of regulation References 
Apoptosis 
 
In murine beta-pancreatic cell, O-
GlcNAcylation of anti-apoptotic AKT1 
protein correlates with cell apoptosis 
 




In Xenopus leavis oocytes, reduction of O-
GlcNAcylation prevents G2/M transition 
 
(Dehennaut 





In human cells, O-GlcNAc modifies and 
stabilizes BMAL1 and CLOCK, two 
regulators of circadian rhythms.  




In murine, knock-out of Ogt leads to loss of 
embryonic stem cell viability (report 
described in more depth in the paragraph 
2.6 O-GlcNAc and pluripotency) 
 





In monkey fibroblast, excess of O-GlcNAc 







In human, O-GlcNAcylation of RNA 




et al., 2012) 
Translation 
 
In human, O-GlcNAc modifies and 
potentially regulates numerous ribosomal 
proteins 
 
(Ohn et al., 
2008) 
 












Examples  References 
Cancer 
 
O-GlcNAcylation of SNAIL1 initiates 
epithelial-mesenchymal transition 
 





Excess of O-GlcNAc enhances 
cardiac function during trauma 
recovery   
 




O-GlcNAcylation inhibits eNOS 








O-GlcNAcylation of TAU decreases 
TAU aggregation and correlates with 





Table 2-2 Examples of human diseases involving O-GlcNAc. 
 
2.6 Methodology for O-GlcNAc characterization 
2.6.1 Challenges of O-GlcNAc characterization 
 
As stated by Dr. Gerald Hart (discoverer and major expert of the O-GlcNAc 
modification) “It’s hard as hell to study O-GlcNAc” (Hart, 2013). Indeed, 
studying O-GlcNAc is challenging due to its characteristics. Firstly the 
modification is labile, i.e. soon after cell lysis OGA will remove O-GlcNAc from 
protein backbone (Hart and Akimoto, 2009). Secondly, O-GlcNAc 
stoichiometry can reach as low as 2% (Dong et al., 1993), (Rexach et al., 
2010). Thirdly, contrary to phosphorylation, O-GlcNAc has no charge hence 
gel electrophoresis is unable to separate the O-GlcNAcylated from the non-
modified versions of the same protein rendering O-GlcNAc identification 
difficult. Finally, the O-GlcNAc moiety is easily lost during mass spectrometry 
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(MS) fragmentation (Chalkley and Burlingame, 2001). Despite these 
challenges, several research groups have continued to develop new 
techniques to circumvent these limitations. This will be discussed in the 
following sections.  
 
2.6.2 Inhibitors of O-GlcNAc enzymes 
 
The stoichiometry of O-GlcNAc on specific proteins has been shown to vary 
from 2 % to 100 %, but in most cases, the stoichiometry is lower than 10 % 
(Rexach et al., 2010), (Hart and Akimoto, 2009). Therefore, the study of O-
GlcNAc often requires increasing O-GlcNAcylation level by either elevating 
UDP-GlcNAc concentration (Marshall et al., 2004), over-expressing OGT 
(Clark et al., 2003) or knocking-down OGA (Ngoh et al., 2008). However 
numerous studies rely on a faster and easier method which uses OGA 
inhibitors (Macauley and Vocadlo, 2010) (Figure 2-8 A). OGA inhibitors have 
similar mechanisms of action; they mimic native O-GlcNAc by binding and 
blocking OGA catalytic pocket site (Gloster and Vocadlo, 2010). The most 
commonly used OGA inhibitor for O-GlcNAc studies is PUGNAc (Zachara et 
al., 2011), (Park et al., 2005). Indeed, addition of PUGNAc to various human 
cell cultures was shown to result in a 2-fold increase in global O-
GlcNAcylation level. However, the increase of O-GlcNAcylation on specific 
proteins seems to be protein-dependant (Haltiwanger et al., 1998). While 
PUGNAc is more potent towards OGA, it also inhibits hydrolases such as 
lysosomal α- and β-N-acetylhexosaminidases (Gao et al., 2001). Therefore 
results obtained with PUGNAc should be validated using other OGA inhibitors 
with similar functions such as Streptozotocin or Thiamet G. Thiamet G is a 
good alternative for PUGNAc in terms of specificity since Thiamet G was 
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reported to be 35,000 times fold more specific for OGA than for other non-
specific hydrolases (Macauley and Vocadlo, 2010), (Yuzwa et al., 2008). In 
addition to OGA inhibitors, a few inhibitors of OGT have also been developed 
and are now commercially available, such as Alloxan (Konrad et al., 2002) 
and X1 (Gross et al., 2005) (Figure 2-8 B).  
 
Figure 2-9 O-GlcNAc enzyme inhibitors’ structures. 
Figure modified from (Macauley and Vocadlo, 2010), (Konrad et al., 2002) and (Gross et al., 
2005).  
A. OGA inhibitors and, B. OGT inhibitors. 
 
Of note, other non-O-GlcNAc enzymes inhibitors (DON, Azaserine) are 
sometimes used for O-GlcNAc study (Butkinaree et al., 2010). However, DON 
and Azaserine inhibitors do not directly inhibit OGT and OGA; instead they 
target GFAT (Glutamine fructose-6-phosphate amidotransferase) which is the 
third and step-limiting enzyme of the hexosamine biosynthesis pathway 
















2.6.3 O-GlcNAc detection 
 
Detection of O-GlcNAc is usually done by Eastern blot. Native O-GlcNAc 
detection can be performed thanks to the availability of specific antibodies 
(CTD110.6 and RL2) (Zhao et al., 2011) or GlcNAc lectins like the wheat 
germ agglutinin (WGA) (Vosseller et al., 2006).  
Alternatively to the detection of native O-GlcNAc, other methods rely on the 
detection of chemically modified O-GlcNAc. O-GlcNAc can be modified 
through click chemistry (Figure 2-9). In this approach, a genetically 
engineered enzyme (GalT1) first adds an azido-modified galactose (GalNAz) 
on O-GlcNAc (Ramakrishnan and Qasba, 2002). Then, a cycloaddition is 
performed in between the azido group and an alkyne. The alkyne can, for 
example, be linked to a biotin which will be used for detection through an 
avidin-conjugated antibody. Alternatively, biotin-labeled O-GlcNAcylated 
proteins can be enriched by avidin column (Dehennaut et al., 2008).  
 
Figure 2-10 Biotin labeling of O-GlcNAcylated proteins through click chemistry. 
 
Beside click chemistry, O-GlcNAc can also be substituted by dithiothreitol 
(DTT) through a β-elimination-Michael addition (BEMAD). Through BEMAD, 
O-GlcNAc is first eliminated from the protein backbone (β-elimination) leaving 














addition) (Figure 2-10). Subsequently, DTT-modified proteins can be detected 
or enriched with thiopropyl sepharose 6B-conjugated antibody or column 
respectively (Zachara et al., 2011).  
 
Figure 2-11 Scheme representing the β-elimination-Michael addition (BEMAD) performed 
on O-GlcNAcylated proteins. 
Figure modified from (Wells et al., 2002) 
 
 
2.6.4 Mass spectrometry applied to O-GlcNAc characterization 
 
One of the most challenging issues when studying O-GlcNAc lies in precisely 
localizing the O-GlcNAcylation sites by mass spectrometry (MS). As 
previously mentioned, O-GlcNAc moiety is easily lost by collision induced 
dissociation (CID) fragmentation, the most common MS fragmentation mode 
(Chalkley and Burlingame, 2001). Furthermore, signals from ionized O-
GlcNAcylated peptides are often suppressed in favor of non-O-GlcNAcylated 
peptides (Chalkley and Burlingame, 2001). This ionization bias hampers 
shotgun MS strategy used to identify as many O-GlcNAcylated peptides in a 
complex mixture. 
To circumvent the issues arising from CID-MS, a new type of fragmentation 
has been used: electron transfer dissociation (ETD). In contrast to CID which 
uses collision on inert gas; ETD uses electron transfer from radical anion to 
fragment peptides (Kim and Pandey, 2012). Therefore, owing to its softer 
fragmentation, ETD preserves O-GlcNAc moiety enabling the localization of 
native O-GlcNAcylation sites by shotgun MS (Chalkley et al., 2009). However, 






ETD was also shown to favor the formation of +3 or +4 charged peptides 
(Pitteri et al., 2005). As a consequence, small peptides will have a low m/z 
value and will be lost in the noise of low mass range.  
Alternatively, CID can be coupled to BEMAD reaction to localize O-
GlcNAcylation sites. As described previously (2.5.3 O-GlcNAc detection), it is 
possible to substitute O-GlcNAc by a DTT group which is then stable through 
CID fragmentation in shotgun MS (Zachara et al., 2011), (Vosseller et al., 
2005). However, BEMAD reaction is time-consuming and tedious as it 
requires optimizations and several days of preparation (Zachara et al., 2011).  
Besides shotgun MS, a targeted MS method called multiple reaction 
monitoring (MRM-MS) might be benifical when working on a pre-selected O-
GlcNAcylated protein. So far, only one report has demonstrated the abilty of 
MRM-MS to detect an O-GlcNAcylated peptide from human TAU protein 
recombinantly expressed in E. coli but not on native O-GlcNAcylated peptide 
(Yuzwa et al., 2011).    
 
2.7 O-GlcNAc and pluripotency 
 
As previously stated (see 2.4 O-GlcNAc biological function), O-GlcNAc 
regulates a variety of cell mechanisms. Of importance for the present thesis is 
the involvement of O-GlcNAc on pluripotent stem cells phenotype such as 
pluripotency maintenance and differentiation.   
To date, a few studies have started to establish a link between O-GlcNAc and 
pluripotency. Some of the key reports are as follows:   
- O-GlcNAc transferase knock-out is lethal for mESC (Shafi et al., 2000). In 
this study, the authors first reported the inability to produce a stable mESC 
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line with Ogt knock-out. mESC with Ogt lox-P flanked lost viability 144h after 
Ogt conditional deletion. Finally, by demonstrating the inability to create Ogt-
deleted mouse using Cre-loxP system mouse breeding, the authors 
concluded that Ogt is essential during early embryogenesis.  
-  O-GlcNAc regulates morphogenesis during zebrafish development 
(Webster et al., 2009). In this paper, increasing and decreasing global O-
GlcNAcylation level led to similar defects during zebrafish development: 
increased cell death, a reduction of all three lineages as well as morphology 
defects.     
- Excess of O-GlcNAc suppresses spontaneous cardiogenesis in mESC (Kim 
et al., 2009). Here, Kim et al. observed that increasing global O-
GlcNAcylation level reduced the number of spontaneously differentiating 
mESC expressing cardiac markers. Phenotypically, increase in O-
GlcNAcylation also reduced the number of beating aggregates.   
- Excess of O-GlcNAc enhances mESC pluripotency (Jang et al., 2012). In 
this study, elevated O-GlcNAcylation level enhanced mESC self-renewal and 
fibroblast reprogramming. In differentiating mESC, elevated O-GlcNAcylation 
also reduced pluripotency loss and reduced the expression of differentiation 
lineage markers. Of importance, OCT4 transcription activity was reported as 
regulated by O-GlcNAc. O-GlcNAc-defective OCT4 led to defect in mESC 
self-renewal and fibroblast reprogramming. 
In addition, several mESC essential transcription factors (SOX2, ZFP281, 
NURF, HCF-1) were reported as modified and potentially regulated by O-
GlcNAc (Myers et al., 2011). 
Even though these few reports have started to shed light on the relationship 
between O-GlcNAc and mESC, there hasn’t been any publication reporting 
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the role of O-GlcNAc in hPSC. However, the role of O-GlcNAc in hPSC might 
differ from mESC, as mESC and hPSC are well known to diverge in both 
pluripotency maintenance requirement and differentiation potential. For 
example, leukemic inhibitor factor is required for mESC culture but not for 
hESC (Ginis et al., 2004). In addition, trophoblast lineage cannot be derived 
from mESC differentiation but can be obtained from hESC differentiation 
(Douglas et al., 2009). 
 
2.8 Human pluripotent stem cell 
 
Human pluripotent stem cells (hPSC) are cells with the ability to self-renew 
and differentiate to the three germ layers (meso-, endo-, ecto-derms). There 
are currently two sources of hPSC which are human embryonic stem cells 
(hESC) and induced pluripotent stem cells (iPSC).  
hESC were first isolated by Thomson group in 1998 from the inner cell mass 
of human blastocyst (Thomson et al., 1998). Numerous studies have shown 
the potential of hESC to differentiate into specific cells such as neurons 
(Bardy et al., 2012), cardiomyocytes (Lundy et al., 2013), hepatocytes 
(Ramasamy et al., 2013), beta cells (Bose et al., 2012) and osteoblasts 
(Arpornmaeklong et al., 2011). Therefore, those studies have suggested the 
potential use of hESC for regenerative medicine to treat neurodegenerative 
diseases, heart failures, liver dysfunction, diabetes, skeletal tissue injuries 
and others. In addition, such differentiated cells could be used by 
pharmaceutical companies for drug screening when appropriate drug models 
are lacking (Ebert and Svendsen, 2010). However, differentiation protocols 
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are still limited in its efficiency thus resulting in incomplete differentiation and 
a heterogeneous cell population (Rao, 2007), (Erdo et al., 2003).  
More recently, Yamanaka et al. demonstrated that hPSC can be obtained 
from fibroblast instead of embryos. Here, fibroblast can be reprogrammed to a 
pluripotant state by inducing the expression of OCT3/4, SOX2, c-MYC, and 
KLF4 (Takahashi and Yamanaka, 2006); the resulting cells are known as 
human iPSC. Similar to hESC, iPSC display pluripotency properties and can 
be directed to various cell types: neurons (Hu et al., 2010), hematopoietic 
cells (Choi et al., 2009b), cardiomyocytes (Fujiwara et al., 2011) and 
enterocytes (Spence et al., 2011). One significant advantage that iPSC offer 
as compared to hESC is that they can potentially be used for autologous cell 
therapy. Contrary to hESC which might trigger immune responses when 
transplanted into a patient, iPSC could be reprogrammed directly from 
patients own cells and transplanted without immune rejection (Guha et al., 
2013).   
Overall, hPSC hold great promise for developmental biology, drug discovery 
and regenerative medicine (Jensen et al., 2009), (Grabel et al., 2012). 
However, before hPSC can be clinically relevant, differentiation protocols 
need to be refined; and cues controlling differentiation need to be further 
understood. 
 
2.9 Polycomb group proteins 
 
Polycomb group (PcG) proteins were discovered by Edward B. Lewis in 1947. 
PcG proteins were first identified in Drosophila melanogaster as repressors of 
Homeotic (Hox) genes regulating segmental identity during development 
28 
 
(Grimaud et al., 2006). PcG proteins are now known as epigenetic repressors 
and are essential regulators of development and pluripotency (Medvedev et 
al., 2012).   
 
2.8.1 Polycomb Repressive Complexes 
 
In mammals, PcG proteins comprise more than twenty proteins that associate 
together to form two distinct protein complexes called polycomb repressive 
complex 1 and 2 (PRC1 and 2). Those complexes are usually presented 
through a ‘classical’ model for which PRCs act in sequence as shown in 
Figure 2-11 (Spivakov and Fisher, 2007), (Simon and Kingston, 2009). Briefly, 
PRC2 is recruited to the chromatin and tri-methylates the lysine 27 of histone 
3 (H3K27me3). Through H3K27me3 mark, PRC1 is recruited to the chromatin 
and mono-ubiquitinates the lysine 119 of histone 2A (H2AK119ub) (Vissers et 
al., 2008). H3K27me3 and H2AK119ub marks function to repress gene 
expression. 
 
Figure 2-12 Overview of the ‘classical’ model of PRCs function. 
First, PRC2 tri-methylates the lysine 27 of histone 3 (H3K27me3) thanks to EZH enzyme. Then 
PRC1 component, CBX, binds to H3K27me3 and recruits PRC1 complex. PRC1 ubiquinitates 
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the lysine 119 of histone 2A (H2AK119ub) thanks to RING1B (also refered as RING2) enzyme. 
H3K27me3 and H2AK119ub repress gene expression.    
Figure from (Vissers et al., 2012). 
 
PRC2: 
PRC2 recruitment to histones is not fully understood but has been 
hypothesized as involving one or several of the following: OCT4 protein, YY1 
protein,  CpG islands and non-coding RNA (Simon and Kingston, 2009).  
PRC2 has three main components: EZHs, EEDs and SUZ12 proteins (Figure 
2-12) (Simon and Kingston, 2009). EZH2 and to a lesser extend EZH1 are 
PRC2 catalytic subunits di- and tri-methylating H3K27 (Margueron et al., 
2008); while SUZ12 and EEDs enhances EZHs’ enzymatic activity (Pasini et 
al., 2004), (Montgomery et al., 2005).  
 
Figure 2-13 Composition of PRC2 and PRC1. 
Figure modified from (Margueron and Reinberg, 2011) 
 
PRC1: 
PRC1 has four major components: RINGs, CBXs, HPHs and 
BMI1/MEL18/NSCP1 proteins. PRC1 is recruited through CBXs proteins 









there are a total of 5 different CBX proteins (CBX2, 4, 6, 7 and 8) which bind 
to specific gene subsets (Vincenz and Kerppola, 2008). As CBX proteins 
binding to RING2 is exclusive (e.g. RING2 can only bind to one CBX protein 
at a time) (Bezsonova et al., 2009), (Wang et al., 2010a); CBX proteins 
orientate PRC1 repression towards specific gene subsets. PRC1 catalytic 
activity is conferred by RINGs protein: RING1 (also referred as RING1A) and 
RING2 (also referred as RNF2 and RING1B) (Wang et al., 2004). In vitro, 
only human RING2 have been demonstrated as possessing a catalytic 
activity on H2A by itself, whereas human RING1 is not able to ubiquitinylate 
H2A by itself (Wang et al., 2004). In mouse, single knock-out of either Ring1 
or Ring2 results in depletion of H2Aub (De Napoles et al., 2004). In addition, 
the double knock-out of Ring1 and Ring2 results in an apparent loss of 
H2Aub (De Napoles et al., 2004). These results suggest that RING proteins 
are necessary for H2A ubiquitinylation. In addition, there seems to be an 
overlapping function for RING1 and RING2. Even though RING1 does not 
have an ubiquitinylation activity on its own in vitro, it might have catalytic 
activity through its binding with other partners. The last component of PRC1, 
BMI1 / MEL18 / NSCP1 enhances the ubiquitinylation activity of RING2 
protein (Cao et al., 2005).  
Transcriptional repression originating from PRCs marks (H3K27me3 and 
H2Aub) is not fully understood. To explain the repression, several 
mechanisms have been hypothesized including: chromatin compaction, 
recruitment of DNA methyltransferases, recruitment of RNAi machinery and 
blockage of RNA polymerase II elongation (Cao et al., 2005), (Kim et al., 





In Drosophila,  a third polycomb complex, PhoRC, might function to recruit 
PRC2 (Klymenko et al., 2006). Even if the existence of a mammal PhoRC 
ortholog has not been demonstrated; PhoRC Pho protein was shown to have 
a mammalian ortholog: YY1 (Atchison et al., 2003). Interestingly, YY1 
functions as a DNA-binder transcription factor which not only suppresses 
transcription (like other PcG proteins) but also activates transcription of some 
genes (Shrivastava and Calame, 1994). Even if YY1 doesn’t directly belong to 
PRC1 and 2 cores in mammals, YY1 interacts with PRC2 and might therefore 
be used to recruit PRC2 to DNA and histones (Satijn et al., 2001).  
 
As shown in Figure 2-12, the composition of PRCs complexes can change to 
give rises to different variants. The resulting PRCs variants might differ in 
functions and gene targets (i.e. the different CBXs proteins confer gene-
targeting specificity to PRC1, as described above). In addition, the PcG 
complexes are also known to interact with non-PcG protein further increasing 
PRCs diversity and functions (Simon and Kingston, 2009).  
PcG repression is complemented by Tritorax group (trxG) which activates 
gene expression thought H3K4 trimethylation (Schuettengruber et al., 2007).  
In addition, PRCs H3K27me3 and H2Aub marks can be removed by 
demethylase enzymes (UTX, JMJD3) and deubiquitinase enzymes (USP16, 
USP21, BAP1) respectively (Hong et al., 2007), (Cao and Yan, 2012). 
 
The model presented here is considered as the ‘classical’ model which 
probably is a simplification of PRCs action. Indeed, this ‘classical’ model has 
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been challenged by several reports. For example, PRC1 can ubiquitinylate 
some of its target in the absence of PRC2; suggesting that some PRC1 
variants are PRC2-independant while other PRC1 variants are PRC2-
dependant (Schoeftner et al., 2006), (Tavares et al., 2012). In this PRC2-
independent mechanism, RYBP protein replaces CBXs protein in PRC1 as 
chromatin-binding protein (Morey et al., 2013). Additionally, the chromatin 
compaction initiated by PRC1 requires RING2 presence but does not seem to 
require RING2 ubiquitinylation activity (Eskeland et al., 2010).   
 
2.8.2 PcG and pluripotency 
 
Since their discovery in 1947, PcG have been shown to regulate Drosophila 
development through the repression of Hox gene (Grimaud et al., 2006). 
However PcG represses the transcription of many more genes, including 
many key developmental transcription factors (DLX, IRX, LHX, POU, PAX) 
and signalling molecules (TGFβ, BMP, Wnt, FGF) in mESC and hESC (Boyer 
et al., 2006), (Lee et al., 2006). Futhermore, in hESC, half of PRC2 binding 
sites co-occupy with three essential hESC transcription factors: NANOG, 
OCT4 and SOX2 (Lee et al., 2006). Some differentiation genes repressed by 
PcG in cultured ESC become de-repressed during differentiation (Boyer et al., 
2006). Also during differentiation, PcG has been suggested to switch its target 
to repress pluripotent genes (Luis et al., 2012). 
In mESC, PcG proteins loss of function does not generally affect the 
maintenance of pluripotency (Pasini et al., 2004), (Chamberlain et al., 2008); 
instead PcG loss of function perturbs lineage restriction (Table 2-3) (Richly et 
al., 2011). Interestingly, RING1 and RING2 also seem to be essential for 
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maintaining pluripotency as mouse double knock-out of Ring1 and Ring2 led 
to mESC spontaneous differentiation (Endoh et al., 2008). 
 
Table 2-3 Effect of PcG protein loss of function on mESC. 
From (Surface et al., 2010) 
 
2.8.3 PcG and O-GlcNAc 
 
PcG proteins are known to be heavily modified and regulated by a variety of 
post-translational modifications including: ubiquitinylation, sumoylation, 
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phosphorylation and acetylation (Niessen et al., 2009).  Interestingly, some 
PcG proteins have also been reported as being O-GlcNAcylated.  
In Drosophila, PRC1 HPHs ortholog (whose function remain unknown) was 
shown to be O-GlcNAcylated (Gambetta et al., 2009). The same study also 
reported that almost half of O-GlcNAcylated DNA-binder proteins co-localize 
with PRC1 HPHs ortholog. Also, whereas OGT loss neither affects PRC2 
recruitment nor H3K27me3 level; OGT loss reduced HPHs ortholog 
recruitment and PcG mediated repression (Gambetta et al., 2009), (Myers et 
al., 2011). Furthermore in mouse brain, one of the PRC1 HPHs, HPH3, was 
reported as O-GlcNAcylated on T238 (Chalkley et al., 2009). Overall, those 
data suggest that whereas O-GlcNAc might not be so important for PRC2; O-
GlcNAc might control PRC1 function through HPHs ortholog and potentially 
other PRC1 proteins.  
Another PcG protein, YY1 was also reported as O-GlcNAcylated (Hiromura et 
al., 2003). Moreover, it has been described that YY1 O-GlcNAcylation 
disrupts YY1-Rb protein association allowing YY1 to bind DNA (Hiromura et 
al., 2003) (see Figure 2-7).   
 
The link between O-GlcNAc and PcG is not limited to the O-GlcNAcylation of 
some PcG proteins as loss of mouse PRC2 EED or SUZ12 result in 
decreased expression of OGT protein (but not mRNA) and consequently an 
alteration of O-GlcNAcylation level (Myers et al., 2011). Those data suggest 
that PRC2 might regulate factors stabilizing OGT.   
Interestingly, in Drosophila, the OGT gene was first identified through a 
mutation giving a phenotype similar to PcG proteins with an ectopic 
expression of Hox genes (Ingham, 1984). Due to this similarity, the OGT gene 
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was first classified as a PcG gene and named super sex comb. It was only 25 
years later that super sex comb was characterized as OGT (Gambetta et al., 




O-GlcNAc is an abundant post-translational modification involved in many 
cellular processes. Previous studies have started to establish a link between 
mESC pluripotency and O-GlcNAc, however the corresponded effect in hPSC 
have yet to be demonstrated. The implication of O-GlcNAc for hPSC might be 
very diverse. On a global point of view, O-GlcNAcylation might regulate 
pluripotency maintenance and differentiation. More specifically, O-GlcNAc 
might potentially modify and regulate numerous transcription, epigenetic tool 
and polycomb proteins. Hence, the knowledge of hPSC phenotype regulation 
by O-GlcNAc will be beneficial to develop hPSC potential for cell 
transplantation and biotechnology. 
36 
 
CHAPTER 3 - MATERIALS AND METHODS 
 
3.1 Chemicals and inhibitors 
 
PUGNAc (Sigma-Aldrich) and Thiamet G (Tocris Bioscience) were solubilized 
in water and anhydride DMSO respectively to a working concentration of 15 
mM for both. In the feeding experiments, PUGNAc and Thiamet G were 
added in the culture media at a final concentration of 100 μM and 42 μM 
respectively. Appropriate controls with either addition of water or DMSO were 
used in the respective experiments.    
Standard O-GlcNAcylated CREB peptide (TAPT(S-O-GlcNAc)TIAPG, 
M=1117.5 g.mol-1) (Invitrogen) was reconstituted in 40 mM ammonium 
bicarbonate (pH 8). Before LC-MRM-MS analysis, the standard O-
GlcNAcylated CREB peptide was further diluted in LC-MS buffer to the final 
composition of 1 % formic acid, 2 % methanol. Mixtures of O-GlcNAcylated 
peptide with human embryonic stem cells (hESC) lysate were prepared by in-
gel trypsin-digestion of 5 µg of whole hESC lysate as described below. The 
tryptic digest from whole hESC lysate was mixed with the standard O-
GlcNAcylated CREB peptide at the following ratios 5:95; 2.5:97.5; 1:99 (O-
GlcNAcylated peptide: hESC lysate) in LC-MS buffer (final composition of 1 % 
formic acid, 2 % methanol). 
 
3.2 Cell culture 
 




Human embryonic stem cell line, HES-3 (46 X,X) (ES Cell International) was 
cultured as described previously (Choo et al., 2006). Briefly, hESC were 
seeded on Matrigel (BD Bioscience)-coated tissue culture dishes and 
maintained at 37ºC under 5 % of CO2 with fresh conditioned media changed 
daily (Choo et al., 2006). Conditioned media were harvested from mitomycin-
C (Sigma) treated immortalized mouse embryonic fibroblast cultured with KO 
media supplemented with 10 ng/mL fibroblast growth factor-2 (FGF-2). KO 
media were composed of KnockoutTM DMEM supplemented with 20 % 
KnockoutTM serum replacement, 0.1 mM MEM non-essential amino acid, 2 
mM L-glutamine, 1 X penicillin streptomycin, 1 X 2-mercaptoethanol. Weekly, 
hESC were routinely passaged mechanically using StemPro® EZPassageTM 
(Life Technologies). For the feeding experiment, fresh conditioned media 
were supplemented with 100 μM of PUGNAc and fed to the cultures daily. 
Induced pluripotent stem cells, ESIMR90 and ES4SKIN, reprogrammed 
respectively from fetal lung fibroblast (IMR-90) and neonatal foreskin 
fibroblast respectively were kindly provided by Prof. James Thomson 
(Genome Centre of Wisconsin, U.S.A.). The iPSCs were cultured at 37ºC 
under 5 % of CO2 on hESC-qualified Matrix (BD Bioscience) with conditioned 
media supplemented with 100 ng/mL of FGF-2. Weekly, iPSCs were routinely 
passaged mechanically using StemPro® EZPassageTM (Life Technologies). 







Fetal lung fibroblast, IMR-90, (CCL-186TM) and neonatal foreskin fibroblast 
(CRL-2522TM) were obtained from ATCC. The fibroblasts were cultured at 
37ºC under 5 % of CO2 with DMEM high glucose media supplemented with 10 
% fetal bovine serum (FBS, Thermo Scientific), 25 U/mL penicillin, 25 μg/mL 
streptomycin and 2 mM L-glutamine. 
Unless stated, all culture medium components were obtained from Life 
Technologies.  
 
3.2.3 Stem cell differentiation  
 
To induce spontaneous differentiation, hESC or iPSC were harvested as 
clumps using StemPro® EZPassageTM (Life Technologies). The clumps were 
cultured as embryoid bodies (EB) in an ultra-low attachment plate (Corning) 
containing EB-media. EB-media were composed of KnockoutTM DMEM 
supplemented with 20 % FBS (Thermo Scientific), 25 U/mL penicillin, 25 
μg/mL streptomycin, 2 mM L-glutamine, 0.1 mM NEAA and 0.1 mM of 2-
mercaptoethanol. EB media were routinely replaced with fresh media every 2 
days. After 7 days of differentiation, the EB clumps were directly seeded on 
gelatinized culture dishes.  
In the feeding experiment, EB were treated with 100 μM of PUGNAc. 
PUGNAc was added 24 h after differentiation induction. Subsequently, the EB 
media supplemented with 100 μM PUGNAc were refreshed every alternate 
day. Alternatively, when feeding experiment were performed with Thiamet G, 
42 μM of Thiamet G was used instead of 100 μM of PUGNAc.  
Neuroprogenitors generated from hESC by directed differentiation were 
obtained as previously described (Bardy et al., 2012), (Wu et al., 2012). 
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Briefly, hESC were harvested as clumps using StemPro® EZPassageTM and 
cultured as EB in an ultra-low attachment plate supplied with EB-medium for 
3 days. EB cells were then seeded on laminin-coated plates and cultured in 
N2B27 medium (DMEM/F-12 GlutaMAXTM, 1 X N2 supplement, 1 X B-27® 
minus Vitamin A, 1 % non-essential amino acids, 1 mM L-glutamine, 25 U/mL 
2-mercaptoethanol) supplemented with 500 ng/mL of recombinant human 
Noggin Fc Chimera (R&D Systems) for 10 days (medium was routinely 
refreshed every 2 days). Thereafter, cells were harvested as clumps and 
cultured in an ultra-low attachment plate supplied with N2B27 medium 
supplemented with 20 ng/mL epidermal growth factor (EGF) (Peprotech) and 
20 ng/mL of FGF-2 for 7 days (media were routinely refreshed every 2 days). 
Neurospheres obtained here were seeded on laminin-coated plates and 
cultured with N2B27 medium supplemented with EGF and FGF-2. Two days 
after seeding, N2B27 medium was replaced with fresh medium supplemented 
with EGF, FGF-2 and 100 μM PUGNAc. Cells were harvested for real-time 
quantitative reverse-transcription polymerase chain reaction (qRT-PCR) 
analysis 24 h after PUGNAc addition.  
Unless stated, all culture medium components were obtained from Life 
Technologies.  
 
3.2.4 Bacteria work 
 
Lysogeny broth (LB) agar plates were prepared by autoclaving a mixture of 
22.5 g of LB broth powder, 13.5 g of agar powder and 900 ml milli-Q® water. 
After sterilization by autoclave, the mixture was allowed to cool down at RT 
for 15 min before adding the appropriate antibiotics (final concentrations were 
as follow: Ampicilin 100 µg/mL; Chloramphenicol 25 µg/mL; Kanamycin 50 
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µg/mL). The mixture was then poured into petri dishes (30mL per petri dish) 
and allowed to gel for 1 h at RT inside a BSC. LB agar plates were then 
stored at 4ºC before subsequent use. 
LB media were prepared by autoclaving a mixture of 22.5 g LB broth powder 
and 900ml of milli-Q® water. LB media were then stored at 4ºC before use.  
Escherichia coli (E. coli) lines (subcloning efficientTM DH5αTM competent cells 
(Invitrogen) and XL10-Gold® Ultracompetent cells (Stratagene)) were either 
streaked on LB agar plates or culture in LB media supplemented with 





For recombinant expression of HA-RING2 into hPSC, human RING2 DNA 
was isolated from MGC RING2 cDNA (#4285715, Thermo Scientific) and 
cloned into pCMV-HA Ampr vector (#631604, Clontech) to create pCMV-HA-
RING2 Ampr. Next, the HA-RING2 sequence from pCMV-HA-RING2 Ampr 
was isolated, amplified and inserted into a second expression vector (pCHEF 
Ampr, generously provided by Dr. Jimmy Chao, Bioprocessing Technology 
Institute, Singapore) to create pCHEF-HA-RING2 Ampr (see Figure 3-1 for an 




Figure 3-1 Overview of the cloning strategy to create pCHEF-HA-RING2 Ampr. 
 
For the cloning experiment, DNA inserts (RING2, HA-RING2) were first 
amplified from their respective plasmids by PCR using Platinium® Pfx 
Polymerase (Life technologies) and the specific primers listed in Table 3-1. 




RING2 F 5’-TAGAGAATTCGGATGTCTCAGGCTGTGCAGAC-3’ 64 EcoRI 
RING2 R 5’-GACGCTCGAGTCATTTGTGCTCCTTTGTAG-3’ 63 XhoI 
HA-RING2 F 5’-TATAAAGCTTGCGGGCCCACCATGTACCCATA-3’ 64 HindIIII 
HA-RING2 R 5’-GACGCTCGAGTCATTTGTGCTCCTTTGTAG-3’ 63 XhoI 
 
Table 3-1 List of primers used for the cloning of RING2.   
Primers are indicated with their respective melting temperature (Tm) and inserted restriction 
sites. 
 
After the PCR amplification, the DNA was purified on 1% agarose gel with 1 X 
GelStarTM (Lonza). The corresponding DNA band was excised and the DNA 
was extracted using the QIAquick Gel Extraction Kit (QIAGEN) according to 
manufacturer’s instruction.  
About 2 µg of each insert and plasmid were individually restricted for 2 h at 
37ºC using appropriate restriction enzymes and buffer (EcoRI, XhoI, HindIII 















The appropriate amount of insert was then ligated with 100 ng of linearised 
plasmid using T4 DNA ligase (Promega) according to manufacturer’s 
protocol.  
The newly created plasmids (pCMV-HA-RING2 Ampr or pCHEF-HA-RING2 
Ampr) were used to transform Subcloning efficientTM DH5αTM competent cells 
(Invitrogen) using the heat-shock method according to the supplier’s protocol.    
Plasmids from transformed clones were isolated using the Wizard® Plus SV 
minipreps DNA purification system (Promega). Plasmids sequences were 
confirmed by DNA sequencing (Integrated DNA Technologies). 
For scale-ups, plasmids were isolated using the Plasmid Midi kit (QIAGEN) 
from 100 mL overnight cultures.   
 
3.4 Site-directed mutagenesis 
 
Site-directed mutagenesis was performed on pCHEF-HA-RING2 Ampr using 
QuickChange® II XL site-directed mutagenesis kit with the specific primers 
listed in Table 3-2. Primers were designed following the manufacturer’s 
protocol to mutate specific RING2 codons (coding for the residues T250, 
S251 and S278) into codons coding for alanine residues. Four plasmids 
coding for mutated copies of HA-RING2 were obtained T250A; S251A; TASA 













Table 3-2 List of specific primers used for site-directed mutagenesis 
Mutated codon is indicated in bold.  
 
3.5 Transfection of hESC with lipofectamine® 2000 
 
Transfection of hESC was performed with lipofectamine® 2000 (Life 
technologies) according to manufacturer’s protocol. Briefly, for one 6 cm dish 
of hESC seeded, the cells were transfected two days after passaging (~30 % 
confluency). hESC were first fed as described in paragraph 3.2.1 Human 
pluripotent stem cells. Lipofectamine mixture (30 μL of lipofectamine® 2000 + 
300 μL of Opti-MEM® (Life technologies)) and plasmid mixture (10 μg of 
appropriate plasmid + 300 μL of Opti-MEM®) were individually prepared and 
incubated for 2 min at RT. Lipofectamine and plasmid mixtures were then 
mixed and incubated for an additional 5 min at RT. The resulting mixture was 
then added to the hESC and incubated for 48 h at 37ºC under 5 % of CO2. 
After 48 h incubation, hESC were harvested (as described in 3.7 Protein 
harvest) for analysis.  
 
3.6 Flow cytometry analysis 
 
For fluorescence activated cell sorter (FACS) analysis, 2 x 105 cells were 
harvested by trypsin (Life Technologies) treatment and washed with cold 
washing solution (1 % Bovine serum albumin (BSA) in PBS). Cells were 
treated with 100 μL of Fixation medium (Medium A, Life Technologies) for 15 
min. After washing, cells were treated with 100 μL of Permeabilization 
medium (Medium B, Life Technologies) for 15 min in the presence of primary 
antibodies. The following amounts of antibodies were used: 5 μL of anti-
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OCT4 (Santa Cruz), 2 μL of anti-TRA-1-60 (Millipore), and 1μL of anti-SSEA4 
(Biolegend) for 100 μL of permeabilization medium. After washing, cells were 
incubated for 15 min with a goat anti-mouse fluorescein isothiocyanate-
conjugated antibody (Dako, 1:500 dilutions). After a final wash, cells were 
resuspended in 200 μL of washing solution and analyzed by FACScan 
(Becton Dickinson FACS Calibur). 
 
3.7 Protein harvest 
 
Proteins were harvested with the following lysis buffer: 1 % Igepal (Sigma), 50 
mM Tris-HCl and 150 mM NaCl, pH 7.4 supplemented with complete 
protease inhibitor cocktail (Roche). When needed, PUGNAc to a final 
concentration of 50 μM, was added to the lysis buffer to preserve O-GlcNAc 
modifications. Protein concentration was quantified using the 660 nm Protein 




Immunoprecipitation (IP) was performed on a Micro-extractor automated 
instrument (Phynexus). Following lysate quantification using the 660 nm 
Protein Assay kit (as mentioned above), the amount of hESC lysate and 
antibodies used are reported in Table 3-3.  





O-GlcNAc Convance 30 1.2 
RING2 Abcam 5.2 1.3 
hnRNP K Abcam 15 1.5 
HP1γ Abcam 4 1 
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HA Sigma 3.4 0.56 
 
Table 3-3 Quantity of hESC lysate and antibodies used for each immunoprecipitation 
experiment. 
For all IP (except IP anti-HA), hESC lysate refers to the lysate from hESC cultured with or 
without incubation with 100 μM of PUGNAc for 24 h. For the IP experiment using the anti-HA, 
hESC lysate refers to lysate from hESC transfected using Lipofectamine® 2000 and 
appropriate plasmids (HA-RING2, T250A, S251A, TSA and S278A) as described in 3.5 
Transfection of hESC . 
 
For all IP experiment (except IP with anti-O-GlcNAc antibody), protein G 
columns (PhyTip® 200+columns, ProtG affinity resin 5 µL) were used to 
capture the appropriate amount of antibody as indicated in Table 3-3. Excess 
antibody was cleared by a washing solution (137 mM sodium chloride, 2.7 
mM potassium chloride, 10 mM phosphate buffer, pH 7.4). Appropriate 
amount of hESC lysate (see Table 3-3) was passed through the column. 
Following a final wash, bound proteins were eluted in 30 μL of 1X SDS-PAGE 
sample loading buffer (Thermo scientific). The whole eluate was boiled for 5 
min and loaded into a single well of a NuPAGE® 4-12 % SDS-PAGE gel (Life 
technologies) for further analysis as described in paragraph 3.11 Western and 
Eastern blots. 
For IP with the anti-O-GlcNAc antibody, strepatavidin columns (PhyTip® 
200+columns, Streptavidin affinity resin 5 µL) were used to first capture 10 μL 
of biotinylated anti-mouse IgM antibody (Dako). Following a wash, columns 
were used to capture 30 µL of anti-O-GlcNAc antibody (Convance). After 
washing away the antibody excess with the washing solution (137 mM 
sodium chloride, 2.7 mM potassium chloride, 10 mM phosphate buffer, pH 
7.4), 1.2g of hESC lysate was passed through the column. Following a final 
wash, bound proteins were eluted in 30 μL of 1X SDS-PAGE sample loading 
buffer (Thermo scientific). The whole eluate was boiled for 5 min and loaded 
into a single well of a NuPAGE® 4-12 % SDS-PAGE gel (Life technologies) 
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for further analysis as described in paragraph 3.11 Western and Eastern 
blots. 
 
3.9 Biotin labeling of O-GlcNAc by click chemistry 
 
O-GlcNAc modification of O-GlcNAcylated protein was labeled by biotin using 
Click-iT® O-GlcNAc Enzymatic Labeling System kit (Life technologies) 
following manufacturer’s protocol and the scheme decribed in 2.5.3 O-GlcNAc 
detection.  
Briefly, 250 μg of lysate from hESC incubated with 100 μM of PUGNAc for 24 
h were used per reaction. hESC proteins were first purified by 
chloroform/methanol precipitation and resuspended in 30 μL of 1 % SDS in 
20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.9. 
Reaction mixture for the enzymatic labeling of O-GlcNAcylated hESC proteins 
by GalNAz was set up as described in Table 3-4 and incubated at 4ºC for 16 
h. 
Reaction components Volumes (μL) 
hESC proteins 30 
milli-Q® water 36.75 
Labeling buffer C 60 
100 mM MnCl2 8.25 
UDP-GalNAz 7.5 
Gal-T1 enzyme (Y289L) 7.5 
Final volume  150 
 
Table 3-4 Reaction mixture for the labeling of O-GlcNAcylated hESC proteins by GalNAz. 
 
After the incubation at 4˚C for 16 h, the proteins were purified by 
chloroform/methanol precipitation and resuspended in 50 μL of 1 % SDS in 
47 
 
50 mM Tris-HCl, pH 8.0. Then, the reaction mixture for the chemical labeling 
of GalNAz-O-GlcNAcylated proteins was set up as described in Table 3-5 and 
incubated at RT for 20 min with shaking. 
Reaction components Volumes (μL) 
GalNAz-labeled O-GlcNAcylated 
hESC proteins mixture 50 
Biotin alkyne solution  100 
milli-Q® water 10 
CuSO4 solution 10 
Click-iTTM reaction buffer additive 1 10 
Click-iTTM reaction buffer additive 2 20 
Final volume  200 
 
Table 3-5 Reaction mixture for the labeling of GalNAz-labeled O-GlcNAcylated hESC 
proteins mixture by biotin alkyne. 
 
Finally, the chemically labeled proteins Following reaction mixture incubation, 
proteins were purified by chloroform/methanol precipitation and either 
resuspended in 25 μL of 1X SDS-PAGE sample loading buffer (Thermo 
scientific) for Eastern blot analysis (as described in 3.11 Western and Eastern 
blots) or resuspended in 200 μL of 0.1 % SDS, 50 mM Tris-HCl, pH 8 to be 
further processed through biotin-labeled protein enrichment with avidin resin 
(as described in the next section 3.10 Biotin-labeled protein enrichment with 
avidin resin). 
 
3.10 Biotin-labeled protein enrichment with avidin resin 
 
Mixtures obtained through the biotin-labeling (described in 3.9 Biotin labeling 
of O-GlcNAc by click chemistry) contained both non-labeled proteins and 
biotin-labeled O-GlcNAcylated proteins. To enrich for the latter, it required, 
purification with monomeric avidin agarose resin (Thermo scientific) following 
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the manufacturer’s protocol. Briefly, 50 μL of monomeric avidin agarose resin 
were added to a 1.5 mL microcentrifuge tube. The resin was washed with 
PBS and incubated in the reconstituted 200 μL protein mixture in 0.1 % SDS, 
50 mM Tris-HCl, pH 8 for 1 h at RT with rotation. Afterwhich, the resin was 
then washed with PBS and bound-proteins were eluted by boiling the resin in 
1X SDS-PAGE sample loading buffer (Thermo scientific) for 10 min. The 
eluate was finally loaded into a single well of a NuPAGE® 4-12 % SDS-PAGE 
gel (Life technologies) for further analysis as described in 3.11 Western and 
Eastern blots. 
 
3.11 Western and Eastern blots 
 
For Western and Eastern blot analysis, 20 µg of protein lysate (see 3.7 
Protein harvest) diluted in 1X SDS-PAGE sample loading buffer (Thermo 
scientific) was loaded per well of a NuPAGE® 4-12 % SDS-PAGE gel (Life 
technologies). Alternatively, to protein lysate, the whole eluate from IP or 
biotin-labeled experiments (see 3.8 Immunoprecipitation, 3.9 Biotin labeling of 
O-GlcNAc by click chemistry, and 3.10 Biotin-labeled protein enrichment with 
avidin resin) was loaded per well of a NuPAGE® 4-12 % SDS-PAGE gel. 
Proteins were separated by electrophoresis using MOPS SDS running buffer 
(Life technologies). Proteins were then transferred onto PVDF membranes 
using wet electroblotting and transfer buffer composed of 25 mM 
tris(hydroxymethyl)aminomethane (Tris), 192 mM glycine, 20 % methanol and 
80 % milli-Q® water. PVDF membranes were blocked for 1 h at room 
temperature using 100 % Odyssey blocking buffer (LI-COR) and incubated 
overnight at 4ºC under agitation with primary antibodies (See Table 3-6 for 
details). The antibodies were diluted in a solution containing one part 
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Odyssey blocking buffer and one part 0.05 % Tween® 20 in PBS. To visualize 
post-translational modifications, Eastern blots, were prepared similarly to 
Western blots and detected using an anti-O-GlcNAc antibody (Table 3-6).  
Antigen Supplier Dilution for Western blot 
ACTIN Abcam 1:3,000 











CBX8 Abcam 1:1,000 
GSK-3β Cell signaling 1:1,000 
HA Sigma 1:1,000 
hnRNP K Abcam 1:5,000 
HP1γ Abcam 1:1,000 
MSX1 RandD 1:1,000 
NANOG Abcam 1:1,000 
OCT4 Santa cruz 1:500 
OGA Abnova 1:500 
O-GlcNAc 
(CTD110.6) Convance  1:1,000 
OGT Santa cruz 1:500 
PAX6 Abcam 1:1,000 
PPAR g  Millipore 1:2,000 
RING2 Abcam 1:2,000 
RYBP Abcam 1:1,000 
SOX2 Abcam 1:1,000 
 
Table 3-6 List of antibodies used for Western and Eastern blots. 
 
Blots were finally developed using peroxidase-conjugated secondary 
antibodies (Dako; dilution 1:10,000) and visualized with ECL prime Western 
blotting detection reagent (GE Healthcare Life Sciences). Alternatively, blots 
were also developed using fluorescent-conjugated secondary antibodies (LI-
COR, dilution 1:20,000) and visualized using the ODYSSEY® imaging system 
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(LI-COR). Band intensity was measured by densitometry using GelQuant 
software (Biochem Lab Solutions). Bands intensity expression differences 
(∆∗) were calculated at the time point (*) presenting the greatest difference 
between the test experiment (+) and the control (-):  
 
 
3.12 Coomassie staining 
 
Following gel electrophoresis, several SDS-PAGE gels were stained with a 
Coomassie blue solution (1 % Coomassie brilliant blue A250, 10 % acetic 
acid, 30 % methanol in water) for 30 min to reveal protein bands. SDS-PAGE 
gel were then destained with several washes of destaining buffer (10 % acetic 
acid, 30% methanol in water) to reach the desired dye intensity. Coomassie 




Excised Coomassie bands were individually processed for in-gel proteolysis 
as follows. Gel pieces were incubated at 4ºC in a washing solution (50 % 
acetonitrile, 25 mM ammonium bicarbonate) for 24 h. Gel pieces were then 
incubated at 37ºC under shaking for 20 min in a fresh washing solution 
followed by incubation at RT for 10 min in 100 % acetonitrile, and then dried 
down with Savant SpeedVac AES2010 Centrifugal Evaporator (Thermo 
Scientific) followed by incubation at 56ºC for 1 h in 20 mM DTT (reduction). 
After removal of the DTT solution, gel pieces were incubated at RT in the dark 
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for 45 min in 55 mM Iodoacetamide (alkylation) and then washed at RT with a 
series of 10 min incubations using 100 % acetonitrile, 100 mM ammonium 
bicarbonate, 100 % acetonitrile; and finally dried down with Savant 
SpeedVac. Gel pieces were then incubated at 37ºC under shaking for 16 h in 
a solution of 0.02 μg.μL-1 trypsin (Promega) in 25 mM ammonium bicarbonate 
(digestion). Alternatively trypsin was replaced by Glu-C enzyme for the 
digestion. In this case incubation was made with 0.02 μg.μL-1 of Glu-C 
(Promega) in 100 mM Tris HCl, pH 7.8 during 16 h at 37ºC under shaking. 
Following digestions, peptides were extracted with a series of 10 min 
incubations with 100 % acetonitrile with sonication, 100 mM ammonium 
bicarbonate and 100 % acetonitrile. The extraction solutions were combined 
and dried down with the Savant SpeedVac. The total peptide mixture 
extracted from a single band cut was reconstituted in 10 µL of LC-MS buffer 
(1 % formic acid, 2 % methanol). Finally, 2 µL of this sample was injected on 
LC-MS for analysis. 
 
3.14 BEMAD treatment 
 
β-elimination followed by Michael addition (BEMAD) reaction to substitute O-
GlcNAc by DTT on the protein backbone was performed as established 
previously (Wells et al., 2002), (Zachara et al., 2011) to localize O-
GlcNAcylation sites by MS.  
Briefly, 4 parallel IP of anti-RING2 products were purified by 4-12 % SDS-
PAGE electrophoresis. After resolving the bands by electrophoresis, the gel 
was stained by Coomassie blue solution. Each 2 mm-wide band 
corresponding to RING2 (40 kDa) was individually processed through in-gel 
trypsin digestion (as described in 3.13 Proteolysis). After digestion, all 
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peptides were combined and dried down with the Savant SpeedVac and 
resuspended in a 1 % TFA solution in water. The peptides were desalted on a 
C18 reversed-phase spin column (Nest Group Inc.) following the supplier’s 
protocol. The peptides were then subjected to alkaline phosphatase treatment 
(Promega) using the manufacturer’s instruction in order to remove phosphate 
group which can potentially react as well to the BEMAD reaction and lead to 
false positives.  
Proper removal of the phosphate group was confirmed by spiking 18 pmol of 
a standard phosphorylated peptide (VNQIG(pT)LSESIK,  MassPREP peptide 
standard, Waters Corporation) into a peptide mixture obtained from a single 
IP anti-RING2. One half of the mixture was kept at 4ºC and used as control 
while the other half was processed through alkaline phosphatase treatment. 
Both mixtures were individually desalted on C18 reversed-phase spin column 
and reconstituted into 15 μL of LC-MS buffer (1 % formic acid, 2 % methanol). 
From each mixture, 3 μL was injected on LC-MRM-MS and analyzed as 
described in 3.16 LC-MRM-MS analysis. After the alkaline phosphatase 
treatment, the amount of phosphorylated peptide, VNQIG(pT)LSESIK was 
reduced by more than 98 % as quantified by the integration of the peptide on 
the LC-MRM-MS traces (Figure 3-2). Furthermore, the corresponding non-
phosphorylated peptide VNQIGTLSESIK, not present in the control sample, 




Figure 3-2 Phosphatase treatment efficiently removes phosphate groups. 
Comparison of representative LC-MRM-MS traces of anIP anti-RING2 product spiked with 
VNQIG(pT)LSESIK. One half was used as Control (left) whereas the other half was treated 
with alkaline phosphatase (right).  
 
Following the phosphatase treatment, the peptide mixture from the 4 IP anti-
RING2 were dried down and resuspended in 500 μL of a freshly prepared 
BEMAD solution (100 mM dithiothreitol (Sigma), 0.1 % NaOH, 1 % 
triethylamine, pH 12.5) for 2.5 h at 54ºC. BEMAD reaction was stopped by 
addition of TFA to a final concentration of 1 %. BEMAD-treated peptides were 
then desalted on C18 reversed-phase spin column to remove DTT excess. 
DTT-modified peptides were enriched onto a spin column (Thermo Scientific) 






























































supplier’s protocol. The solution of enriched DTT-peptide was acidify, 
desalted on C18 column and dried down. The sample was then resuspended 
in 15 μL of LC-MS buffer (1 % formic acid, 2 % methanol). Finally 5 μL of this 
sample was loaded onto a LTQ Orbitrap XL ETD mass spectrometer (Thermo 
scientific) for MS analysis as described in 3.17 LC-MS2 analysis.  
  
3.15 MRM programming 
 
Transition couples (precursor-fragment ions couples) values were calculated 
for each peptide of interest using Pinpoint Software (Thermo Scientific) and 
can be found in the tables below.  
 
 
Table 3-7 Transition couple values of standard O-GlcNAcylated CREB peptide. 
The asterix (*) indicate fragment ions retaining O-GlcNAc modification. Search of O-GlcNAc 
modified precursor ions also included the oxonium ion (204.09) and the corresponding peptide 
backbone with an O-GlcNAc loss (loss of 203.07). 
Standard O-GlcNAcylated CREB peptide:
TAPT(S-O-GlcNAc)TIAPG 
when retaining O-GlcNAc Charge state m/z
+1 1118.557 T
+2 559.782 A
+3 373.524 b3 270.144 P y8* 946.472
b4 371.192 T y7* 849.419
b5* 661.303 S(O-GlcNAc) y6* 748.372
b6* 762.351 T y5 458.26
b7* 875.435 I y4 357.213




when losing O-GlcNAc Charge state m/z
+1 1118.557 T
+2 559.782 A
+3 373.524 b3 270.144 P y8 743.393
b4 371.192 T y7 646.34
b5 458.224 S(O-GlcNAc) y6 545.292
b6 559.272 T y5 458.26
b7 672.356 I y4 357.213
b8 743.393 A y3 244.129
P
G
b series y series
Q1  m/z Q3 m/z
b series y series





Table 3-8 Transition couple values of standard phosphorylated peptide. 
The asterix (*) indicate fragment ions retaining the phosphate group. 
 





























Q1  m/z Q3 m/z
b series y series
Q1  m/z Q3 m/z




Table 3-9 Transition couple values of ACTIN peptide after trypsin digestion. 
 
 
Table 3-10 Transition couple values of GAPDH peptide after trypsin digestion. 
 

























b series y series
Q1  m/z Q3 m/z
b series y series
Q1  m/z Q3 m/z
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Table 3-11 Transition couple values of α-ENOLASE peptide after trypsin digestion. 


















Q1  m/z Q3 m/z




Table 3-12 Transition couple values of human GSK-3β (Uniprot accession number 
P49841) peptides obtained after trypsin digestion. 
Search for O-GlcNAc modified precursor ions also included the oxonium ion (204.09) and the 
corresponding peptide backbone with an O-GlcNAc loss (loss of 203.07). 
 
GSK-3β (Uniprot accession number, P49841) peptides by tryspin digestion
VTTVVATPGQGPDRPQEVSYTDTK (+O-GlcNAc)


















































b series y series
Q1  m/z
Q3 m/z
b series y series
Q3 m/z
Q1  m/z Q3 m/z





Table 3-13 Transition couple values of human GSK-3β (Uniprot accession number 
P49841) peptides obtained after Glu-C digestion. 
Search for O-GlcNAc modified precursor ions also included the oxonium ion (204.09) and the 
corresponding peptide backbone with an O-GlcNAc loss (loss of 203.07). 
 
 
GSK-3β (Uniprot accession number, P49841) peptides by Glu-C digestion
GSKVTTVVATPGQGPD (+O-GlcNAc)







b7 673.387 V y10 940.473
b8 772.456 V y9 841.404



































b series y series
Q1  m/z
Q1  m/z Q3 m/z
b series y series
Q1  m/z Q3 m/z




Table 3-14 Transition couple values of human GSK-3β (Uniprot accession number 
Q99496) peptides obtained after trypsin digestion. 
Search for O-GlcNAc modified precursor ions also included the oxonium ion (204.09) and the 
corresponding peptide backbone with an O-GlcNAc loss (loss of 203.07). 
 
 
3.16 LC-MRM-MS analysis  
 
Peptide samples were analyzed using a nano-LC-MRM-MS. First, peptide 
separation was performed with a nanoACQUITY UltraPerformance LC® 
(Waters) using solvent A (water, 0.1 % formic acid); solvent B (Acetonitrile, 
0.1 % formic acid); a C18 trap column (Waters Nanoacquity UPLC 180µm x 
20mm 5µM symmetry C18) and an analytical C18 column (Waters 
Nanoacquity UPLC 75µm x 200mm 1.7µm BEH130 C18) which was kept at 
35°C during all the chromatography separation.  
Samples containing the standard O-GlcNAcylated CREB peptide were loaded 
onto the trap column with 99.5 % of solvent A at 6 µl/min for 3 min and eluted 
on the analytical column using a linear gradient from 2 % to 40 % of solvent B 
RING2 peptides (Uniprot acession number, Q99496) peptides by trypsin digestion
TSGNATVDHLSK (+O-GlcNAc)
when losing O-GlcNAc Charge state m/z
+2 716.8493 T
S y11 1128.564
b3 246.108 G y10 1041.532
b4 360.151 N y9 984.51
b5 431.188 A y8 870.467
b6 532.236 T y7 799.43
b7 631.304 V y6 698.383
b8 746.331 D y5 599.314
b9 883.39 H y4 484.287












b series y series
Q1  m/z Q3 m/z
b series y series
Q1  m/z Q3 m/z
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during 15 min at a flow rate of 0.3 µl/min. Samples used for GSK-3β 
identification and quantification were loaded onto the trap column with 99 % 
of solvent A at 6 µl/min for 6 min and eluted on the analytical column using a 
linear gradient from 2 % to 30 % of solvent B during 45 min followed by 
another linear gradient from 30 % to 40 % of solvent B during 10 min at a flow 
rate of 0.3 µl/min.  
Eluted peptides were then sent on a TSQ vantage triple stage quadrupole 
mass spectrometer (Thermo Scientific). Fixed parameters were set as 
follows: 220°C interface heater temperature; 1700 V electrospray needle; 0.4 
Da peak width for Q1; 1.3 mTorr Argon pressure in collision cell; 20 ms dwell 
time per transition for a maximum of 120 transitions. Peptide-specific tuned 
parameters optimized and determined automatically by the Pinpoint software 
(Thermos Scientific) were: S-lens value; collision energy up to a maximum of 
50 V; declustering potential. Acquired data were finally analyzed using the 
Pinpoint Software for detection and integration of LC-MRM-MS traces.  
 
3.17 LC-MS2 analysis  
 
Peptide samples were injected in a nanoACQUITY UltraPerformance LC® 
(Waters) equipped with C18 trap column (Waters Nanoacquity UPLC 180 µm x 
20 mm 5 µM symmetry C18) and analytical column (Waters Nanoacquity 
UPLC 75 µm x 200 mm 1.7 µm BEH130 C18) which was kept at 35°C during 
all the chromatography. Solvent were as follow: solvent A (water, 0.1 % 
formic acid); solvent B (acetonitrile, 0.1% formic acid). Peptide samples were 
loaded onto the trap column with 99 % of solvent A at 12 µl/min for 7 min and 
eluted on the analytical column using a linear gradient from 1 to 40 % of 
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solvent B during 25 min followed by another linear gradient from 40 to 90 % of 
solvent B for 5 min at a flow rate of 0.25 µl/min. 
Eluted peptides were next sent to a SYNAPT-G2 mass spectrometer (Waters) 
with an MSE acquisition mode or data dependent acquisition mode. 
Parameters were set as follows: ESI positive ionization mode; capillary 2300 
V; sampling cone 28 V; extraction cone 4 V; source temperature 80°C; 
desolvation temperature 280°C; desolvation gas flow 800 L/h; low collisional 
energy 4 V; high collisional energy 15-45 V; scan time 0.9 s; mass resolution 
18,000 FWHM; acquisition range: 50-2000 Da. Raw data were analyzed on 
Protein Lynx Global Server 2.4 (Waters) using the uniprot_sprot_human 
database and allowing the following modification: oxidation (+15.995 Da) of 
methionine residues and carbamidomethylation (+57.021 Da) of cysteine 
residues. 
Alternatively to SYNAPT-G2 mass spectrometer (Waters), LTQ Orbitrap XL 
ETD mass spectrometer (Thermo scientific) was used. 
For the analysis of Biotin-QTOF and Biotin-Orbitrap, non-specific proteins 
identified in the Test sample (labelled and enriched proteins) were removed 
by comparison with Control sample (non-labeled and enriched proteins). 
Briefly, proteins identified in Test and Control were compared side by side (1 
was compared to 1* and so on, as seen in Figure 6-1). The number of 
identified peptides was considered as correlated to protein abundance. 
Therefore, proteins with a number of identified peptides in the Control greater 
or equal to the number of peptides in Test were considered as non-specific 




3.18 Real-time qRT-PCR 
 
Total mRNAs were extracted from cells using RNeasy® MiniKit (Qiagen) 
according to the manufacturer’s instructions. Then, cDNAs were produced 
using a SuperScriptTM III First-Strand synthesis system for RT-PCR (Life 
Technologies) according to the manufacturer’s protocol. Real-time 
quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was 
performed using Power SYBR green (Applied Biosystems) and 7500 Real 
time PCR system (Applied Biosystems) with the method: 50ºC for 2 min, 95ºC 
for 10 min, followed by 40 cycles at 95ºC for 15 s and 60ºC for 60 s. Specific 
primers used are listed in Table 3-15.  
Gene name Primer sequences 
AFP F: 5'-TCCCTCCTGCATTCTCTGATG-3' 
  R: 5'-CCTGAGCTTGGCACAGATCC-3' 
AP2 F: 5’-CCATAAAGAGAAAACGAGAGGATGAT-3’ 
 F: 5’-TGGAAGTGACGCCTTTCATG-3’ 
BMP4 F: 5'-TAGCAAGAGTGCCGTCATTCC-3' 
  R: 5'-ACTGAAGCCGGTAAAGATCCC-3' 
CDX2 F: 5'-GGCAGCCAAGTGAAAACCAG-3' 
  R: 5'-GGTGATGTAGCGACTGTAGTGAA-3' 
CEBP a F: 5'-AAGAAGTCGGTGGACAAGAACAG-3' 
  R: 5'-TGCGCACCGCGATGT-3' 
GAPDH F: 5'-GTCGGAGTCAACGGATTTGG-3' 
  R: 5'-AAAGCAGCCCTGGTGACC-3' 
GATA6 F: 5'-GCGGCTTGGATTGTCCTGT-3' 
  R: 5'-TGCGCCATAAGGTGGTAGTTG-3' 
HAND1 F: 5'-TTCTTCGAATCGTGGTGGTTT-3' 
  R: 5'-CAGGAAGTGCAGCGACAAAA-3' 
LPL F: 5'-CTTGGAGATGTGGACCAGCTAGT-3' 
 R: 5'-GAGAGTCGATGAAGAGATGAATGGA-3' 
LHX3 F: 5’-TGGCACAGCAAGTGTCTCAAGT-3’ 
 R: 5’-TGAAAAAGTCGTCCTTGCAGTAAA-3’ 
MAP2 F: 5'-TATCCCAGGACCCCTCACAC-3' 
  R: 5'-TCACTCGGCACCAAGATGG-3' 
MSX1 F: 5'-GCCATGTCTCCTGCATAGCTT-3' 
  R: 5'-CGCTTTTCTTGCCTGGTGTC-3' 
NANOG F: 5'-GAAAAACAACTGGCCGAAGAAT-3' 
  R: 5'-GGTGCTGAGGCCTTCTGC-3' 
NEUROGENIN-2 F: 5’-GGTGCAGCGCATCAAGAAG-3’ 
 R: 5’-GTTTCGCTCGCGGTTGTT-3’ 
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NKX2.5 F: 5'-TCCCCTGGATTTTGCATTCA-3' 
  R: 5'-AGGATCACTCATTGCACGCTG-3' 
OCT4 F: 5'-GGCCGCAGCTTACACATGTT-3' 
  R: 5'-AACGACCATCTGCCGCTTT-3' 
OGA F: 5'-GTGTGGCCAAAAGCATGATG-3' 
  R: 5'-CGGGAGCCATTAGCCTTCA-3' 
OGT F: 5'-GAGGCAGTTCGCTTGTATCGT-3' 
  R: 5'-AATGGGCAGCAGCAAACTCT-3' 
PAX6 F: 5’-CCAGCTTCACCATGGCAAAT-3’ 
  R: 5’-GGCAGCATGCAGGAGTATGAG-3’ 
PPAR g F: 5'-GAACAGATCCAGTGGTTGCAGAT-3' 
  R: 5'-CTTTGATTGCACTTTGGTACTCTTG-3' 
SOX1 F: 5'-CACAACTCGGAGATCAGCAA-3' 
  R: 5'-GTCCTTCTTGAGCAGCGTCT-3' 
TBR2 F: 5’-TGCAGGGCAACAAAATGTATG-3’ 
 R: 5’-GTCTCATCCAGTGGGAACCAGTA-3’ 
 
Table 3-15 List of specific primers used for Real-time qRT-PCR. 
 
Expression differences (∆∗) were calculated at the time point (*) presenting 











As mentioned previously (2.6 O-GlcNAc and pluripotency), even though O-
GlcNAc have been shown to regulate zebrafish morphogenesis and some 
mESC properties, there has not been any published study on the role of O-
GlcNAc in hPSC. Concurrently, mESC and hPSC are known to differ in both 
pluripotency maintenance requirement and differentiation potential. For 
example, leukemic inhibitor factor is required for mESC culture but not for 
hESC (Ginis et al., 2004). In addition, trophoblast lineage cannot be derived 
from mESC differentiation but can be obtained from hESC differentiation 
(Douglas et al., 2009). 
In this chapter, we started to study the importance of O-GlcNAc in hPSC on 
two aspects which are pluripotency maintenance and differentiation. We first 
revealed that, unlike mESC, O-GlcNAcylation does not have a significant 
effect on hESC pluripotency maintenance (4.4 Excess of O-GlcNAc on hESC 
pluripotency). Instead, we report that O-GlcNAc is involved in hPSC 
differentiation mechanism (4.5 Excess of O-GlcNAc on hESC spontaneous 
differentiation) as an excess of O-GlcNAcylation decreases ectoderm 
commitment and increases adipose-related mesoderm lineage of hPSC. 
Interestingly, increasing O-GlcNAcylation level also triggers a counter-
mechanism to balance the upregulation of O-GlcNAc. Overall, our data 
suggests that O-GlcNAc is an important regulator of hPSC differentiation 
towards specific lineages. Data from this chapter have been published in 




4.2 O-GlcNAc transferase and hydrolase expression during 
differentiation 
 
We determined the expression of OGT and OGA in undifferentiated cells, 
differentiating cells and terminally differentiated cells (Figure 4-1). From 
undifferentiated hESC to differentiating hESC embryoid bodies (EB), there 
was a marked decrease in OGT and OGA protein expressions (Figure 4-1). 
OGT and OGA expressions in iPSC ESIMR90 and ES4SKIN were also higher 
than in their parental cells (IMR-90 and Foreskin respectively) prior to 
reprogramming. Overall, OGT and OGA protein expressions were found to 
significantly decrease during the differentiation of hPSC. Our results are 
consistent with previous reports showing a similar decrease in OGT 
expression during zebrafish embryogenesis (Webster et al., 2009) and mESC 
differentiation (Kim et al., 2009b).  
Global level of O-GlcNAcylation was then determined in undifferentiated, 
differentiating and terminally differentiated cells using a specific antibody 
against O-GlcNAc (CTD110.6) (Comer et al., 2001) (Figure 4-1). Using this 
approach, no striking difference was observed on the overall O-GlcNAcylation 
level during hPSC spontaneous differentiation; which was expected as both 
OGT and OGA decrease during differentiation. This however differs from 
previous reports showing O-GlcNAcylation fluctuation in Xenopus laevis 
embryogenesis (Dehennaut et al., 2008b); and O-GlcNAcylation decreases 
during mESC differentiation (Kim et al., 2009b). An explanation for this 
discrepancy might be the inherent differences between mouse and human 
PSC in term of species and pluripotency ability (Schnerch, et al., 2010). Even 
though the overall O-GlcNAcylation was comparable between the human 
samples, differences were observed on specific O-GlcNAc modified proteins 
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during differentiation (Figure 4-1 arrowheads). Some O-GlcNAc modified 
proteins seemed more abundant in either undifferentiated or differentiated 
cells. These results suggest that different O-GlcNAc modified proteins 
contribute differently to the maintenance of stem cell pluripotency and 
differentiation in humans.  
 
Figure 4-1 O-GlcNAc transferase and hydrolase expressions decrease during hPSC 
































Western and Eastern blot analyses of pluripotent cells (hESC; ESIMR90, ES4SKIN); hESC 
embryoid bodies (EB) at day14 and day21 post-differentiation; and terminally differentiated 
fibroblasts (Foreskin, IMR-90). Arrowheads point at O-GlcNAc modified proteins differentially 
expressed between undifferentiated and terminally differentiated cells.  
 
 
4.3 Inhibitors to alter O-GlcNAc level in hESC 
 
To determine if O-GlcNAc is important for the maintenance of pluripotency 
and differentiation, we tested in cell culture the efficiency of OGA inhibitors, 
such as PUGNAc (Haltiwanger et al., 1998) and Thiamet G (Yuzwa et al., 
2008), to increase O-GlcNAcylation level. PUGNAc, used to a final 
concentration of 100 μM (as previously used in other cell lines (Zachara et al., 
2011), (Park et al., 2005)), was able to efficiently increase O-GlcNAcylation 
level in hESC and spontaneously differentiating hESC EB (Figure 4-2). For 
Thiamet G, a working concentration of 42 µM (equivalent to 100 μM of 
PUGNAc) was chosen, based on the reported inhibition constant (Ki) of the 
inhibitors (50 nM and 21 nM for PUGNAc and Thiamet G respectively) 
(Macauley and Vocadlo, 2010). Similar to PUGNAc, Thiamet G was able to 
efficiently increase O-GlcNAcylation level in hESC EB (Figure 4-2). Hence, for 
all subsequent feeding experiments, the concentrations of PUGNAc and 
Thiamet G used were maintained at a final concentration of 100 μM and 42 
μM respectively. 
Unfortunately, the addition of commonly used OGT inhibitors (Alloxan and X1) 
to hESC and iPSC cell culture did not result in significant decrease of global 
O-GlcNAcylation level (data not shown). We therefore decided not to make 




Figure 4-2 O-GlcNAc hydrolase inhibitors (PUGNAc, Thiamet G) increase global level of 
O-GlcNAc.   
 
4.4 Excess of O-GlcNAc on hESC pluripotency 
 
Next, we investigated the effect of altering O-GlcNAc level on the routine 
culture of hESC. We maintained hESC in the presence of 100 μM of PUGNAc 
to increase O-GlcNAcylation level. After 2 weeks of culture, even though the 
O-GlcNAcylation level was up-regulated (Figure 4-3 A), the protein 
expression of pluripotency markers such as SOX2, NANOG remained 
comparable by Western blot analysis (Figure 4-3 B). Similarly, the expression 
of three additional pluripotency markers tested (OCT4, TRA-1-60, SSEA 4) 
remained identical by FACS analysis (Figure 4-3 C). All together, these data 
allow us to conclude that O-GlcNAc level is not involved in the maintenance 


















Figure 4-3 O-GlcNAc level does not affect the maintenance of hESC pluripotency. 
A. Eastern blot; B. Western blot; and C. FACS analysis monitoring pluripotency markers 
(SOX2, NANOG, OCT4, SSEA4, TRA-1-60) in hESC after 1 and 2 weeks treatment with 100 
μM of PUGNAc. For FACS analysis, grey curves and white curves are representing 
respectively the non-incubated and incubated samples with primary antibodies. Doted lines 
mark the fluorescence peak for each individual FACS analysis. 
 
 
4.5 Excess of O-GlcNAc on hESC spontaneous differentiation 
 
4.5.1 Excess of O-GlcNAc by PUGNAc 
 
The alteration of O-GlcNAcylation level and its effect on hESC differentiation 
have been evaluated. For this purpose, we chose to spontaneously 
differentiate hESC as EB because it allows hESC to differentiate into any cell 
lineage (Itskovitz-Eldor et al., 2000). Hence, hESC EB were treated with 
PUGNAc to increase O-GlcNAcylation level and the expression of pluripotent 
and differentiation markers were monitored.  
After PUGNAc treatment for 12 days, protein expression of ectoderm markers 
(PAX6, MSX1) were significantly decreased (Figure 4-4 A). These results 






















five additional ectoderm markers (SOX1, MAP2, NEUROGENIN-2, TBR2 and 
LHX3) (Figure 4-4 B).  
 
Figure 4-4 Excess of O-GlcNAc following PUGNAc treatment decreases ectoderm 
marker expressions in spontaneously differentiating hESC. 
hESC EB were treated with 100 μM of PUGNAc for 12 days. Differentiation was monitored by 
A. Western blots analyses and B. Real-time qRT-PCR. Expression differences (∆*) were 
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Similar to ectoderm, early-mesendoderm markers (BRACHYURY, TBX6, 
FOX2A, CER1, GSC) showed a decrease in mRNA expression at day 4 
(Figure 4-5 A) and showed an even stronger decrease at day 2 (Figure 4-5 
B). In addition, signaling proteins which are known to drive early-
mesendoderm such as NODAL and WNT3A transcriptionally decreased 
(Figure 4-5 B) after addition of PUGNAc suggesting that those signaling 
proteins might actually drive the observed early-mesendoderm decrease. 
 
Figure 4-5 Excess of O-GlcNAc following PUGNAc treatment decreases early-
mesendoderm marker expressions in spontaneously differentiating hESC. 




In spite of the observed global reduction on early-mesendoderm markers 
some other specific mesoderm and endoderm markers did not follow the 

























































































































































































































































































PPAR γ, was found to increase translationally after PUGNAc treatment 
(Figure 4-6 A). This result was confirmed transcriptionally for PPAR γ as well 
as for 3 additional adipose markers (C/EBP α, LPL and AP2) (Figure 4-6 B).  
 
Figure 4-6 Excess of O-GlcNAc after PUGNAc treatment increases adipose marker 
expressions in spontaneously differentiating hESC. 
hESC EB were treated with 100 μM of PUGNAc for 12 days. Differentiation was monitored by 
A. Western blots analysis and B. Real-time qRT-PCR. Expression differences (∆*) were 
calculated as indicated in Materials and Methods. 
 
In contrast to ectoderm and adipose-related mesoderm lineages, other 
lineages tested were minimally affected by excess of O-GlcNAcylation. For 
example, mRNA expressions of cardiac-related mesoderm markers (HAND1, 
NKX2.5), visceral-related endoderm markers (GATA6, AFP), trophectoderm 
markers (CDX2, BMP4), and pluripotency markers (OCT4, NANOG) did not 
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also unaltered by treatment with PUGNAc (Figure 4-7 B). These results 
suggest that O-GlcNAc level does not affect the rate of pluripotency loss 
during hESC differentiation. 
 
Figure 4-7 Excess of O-GlcNAc following PUGNAc treatment has a minimal effect on the 
expression of cardiac, endoderm, mesoderm and pluripotency markers in 
spontaneously differentiating hESC. 
hESC EB were treated with 100 μM of PUGNAc for 12 days. Differentiation was monitored by 
A. Real-time qRT-PCR and B. Western blot. Expression differences (∆*) were calculated as 
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Interestingly, expression of OGT and OGA was altered by PUGNAc 
treatment. By increasing O-GlcNAcylation level, protein (Figure 4-8 A) and 
mRNA (Figure 4-8 B) expression decreased for OGT and increased for OGA. 
These results suggest the existence of an interplay between the O-GlcNAc 
level and the enzymes regulating O-GlcNAc modification where a feed-back 
loop is triggered such that O-GlcNAc has the ability to control the expression 
of its own transferase and hydrolase enzymes. Despite this counter 
mechanism, PUGNAc addition still resulted in a constant increase in O-
GlcNAcylation level during the 12 days of differentiation (Figure 4-8 A).  
 
Figure 4-8 Excess of O-GlcNAc following PUGNAc treatment decreases O-GlcNAc 
transferase (OGT) expression and increases O-GlcNAc hydrolase (OGA) expression in 
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hESC EB were treated with 100 μM of PUGNAc for 12 days. Differentiation was monitored by 
A. Western blots analyses and B. Real-time qRT-PCR. Expression differences (∆*) were 
calculated as indicated in Materials and Methods. 
 
4.5.2 Excess of O-GlcNAc by Thiamet G  
 
To rule out the possibility that our results were attributable to PUGNAc side 
effect, we repeated the same experiments using another OGA inhibitor 
Thiamet G. In general, treatment with Thiamet G resulted in trends similar to 
those observed with PUGNAc: i.e. decrease in ectoderm and increase in 
adipose commitments (Figure 4-9). Thiamet G also resulted in an increase in 
an OGA mRNA expression increase (Figure 4-9).  
 
Figure 4-9 Excess of O-GlcNAc following Thiamet G treatment gave the same effects as 
















































































































































GlcNAc transferase (OGT) and hydrolase (OGA) expressions in spontaneously 
differentiating hESC. 
hESC EB were treated with 42 μM of Thiamet G for 12 days. Differentiation was monitored by 
Real-time qRT-PCR. Expression differences (∆*) were calculated as indicated in Materials and 
Methods. 
 
In addition, Thiamet G had no effect on the rate of pluripotency marker loss 
(OCT4); and had a minimal effect on the expression of other tested lineage 
markers (GATA6, HAND1, CDX2) (Figure 4-10). 
 
Figure 4-10 Excess of O-GlcNAc following Thiamet G treatment, similarly to PUGNAc, 
has a minimal effect on the expression of marker of pluripotency, endoderm, cardiac 
and trophectoderm. 




4.6 Excess of O-GlcNAc on hESC directed differentiation 
 
To confirm that the decrease in ectoderm marker expression was not 
restricted to hESC spontaneous differentiation, neuroprogenitors were 
derived from hESC using a directed differentiation methodology as previously 
described (Bardy et al., 2012). As before, the cells were incubated with 
PUGNAc but only for 24 h. As expected, pluripotency marker (OCT4) 





































































































all seven ectoderm markers tested increased transcriptionally with an 
expression difference ranging from 10 to 3,000 fold (data not shown). This is 
in agreement with increases previously reported for neuroprogenitors from 
hESC  directed differentiation (Bardy et al., 2012), (Wu et al., 2012). In 
addition, PUGNAc treatment of neuroprogenitors led to mRNA decrease of 
PAX6, SOX1, NEUROGENIN-2, TBR2 and LHX3 (Figure 4-11). PUGNAc 
treatment also triggered a decrease in OGT transcription and increase for 
OGA (Figure 4-11). Therefore, the effect of PUGNAc on neuroprogenitors 
from hESC directed differentiation confirmed the data obtained with hESC 
spontaneous differentiation.  
 
Figure 4-11 Excess of O-GlcNAc decreases the expression of ectoderm markers in 
Neuroprogenitors from hESC directed differentiation, similarly to spontaneously 
differentiating hESC. 
Neuroprogenitors from hESC directed differentiation were treated with 100 μM of PUGNAc for 
24 h. Differentiation was monitored by Real-time qRT-PCR. 
 
 
4.7 Excess of O-GlcNAc on iPSC spontaneous differentiation 
 
To demonstrate that the effect of increasing O-GlcNAc level on differentiation 
was not limited to hESC but more broadly applicable to hPSC, we extended 



































































































































































































































































differentiated as EB with the addition of PUGNAc for 12 days to increase O-
GlcNAcylation level. The increase of O-GlcNAcylation led to mRNA 
expression changes in ectoderm, adipose-related mesoderm and early-
mesoderm as previously observed with hESC (Figure 4-12 and Figure 4-13). 
O-GlcNAc hydrolase (OGA) mRNA expression was also decreased, as 
previously demonstrated in hESC (Figure 4-12). Other tested lineage markers 
(OCT4, GATA6, HAND1, CDX2) were minimally affected by PUGNAc 
treatment (Figure 4-13).  
 
Figure 4-12 Excess of O-GlcNAc in spontaneously differentiating iPSC has similar 
effects than in spontaneously differentiating hESC on ectoderm, adipose markers and 
O-GlcNAc enzymes. 
iPSC (ESIMR90) EB were treated with 100 μM of PUGNAc for 12 days. Differentiation was 
monitored by Real-time qRT-PCR. Expression differences (∆∗) were calculated as indicated in 








































































































































Figure 4-13 Excess of O-GlcNAc in spontaneously differentiating iPSC has similar effect 
than in spontaneously differentiating hESC on early-mesendoderm, pluripotency, 
visceral, cardiac and throphectoderm markers. 
iPSC (ESIMR90) EB were treated with 100μM of PUGNAc for 12 days. Differentiation was 
monitored by Real-time qRT-PCR. Expression differences (∆∗) were calculated as indicated in 





To summarise, this chapter investigated the role of O-GlcNAc on hPSC 












































































































































1. The expression of both OGT and OGA genes decrease during hPSC 
differentiation, suggesting that a high level of both OGT and OGA 
proteins might be important for pluripotency maintenance. 
2. O-GlcNAc excess neither affects the maintenance of hESC 
pluripotency nor the loss of pluripotency during hPSC differentiation. 
Our data seem to indicate that further increase in O-GlcNAc level is 
not important for hPSC pluripotency. 
3. O-GlcNAc excess inhibits hPSC ectoderm differentiation and 
enhanced adipose differentiation.  
4. O-GlcNAcylation excess increases OGA expression in hPSC and 
decreases OGT expression in hESC. These data suggest the 
existence of a feedback loop based on OGA and OGT expressions to 
balance O-GlcNAc excess. 
Here, we showed that O-GlcNAcylation, contrary to what was reported in 
mESC (Jang et al., 2012), does not significantly affect hPSC pluripotency 
maintenance. Conversely, we demonstrated that O-GlcNAcylation is 
important for hPSC differentiation specifically towards ectoderm and adipose 
lineages. These findings suggest the existence of O-GlcNAc modified 
proteins regulating hPSC differentiation. The next step for this study will be to 
identify and characterize such O-GlcNAc modified proteins regulating hPSC 
differentiation (CHAPTER 6). However, before continuing the O-GlcNAc 
functional study, we first needed to develop a mass spectrometry method to 
facilitate the discovery and quantification of new O-GlcNAcylated peptides. 




CHAPTER 5 - DEVELOPMENT OF MRM-MS TO 




As previously mentioned, (2.5.4 Mass spectrometry applied to O-GlcNAc) one 
of the biggest challenge in studying O-GlcNAc is to localize O-GlcNAcylation 
sites. O-GlcNAcylation site occupancy is usually identified by shotgun mass 
spectrometry (MS) coupled with an O-GlcNAc chemical labeling and 
enrichment steps (2.5.3 O-GlcNAc detection). The combination of these 
approaches has been instrumental for the large-scale discovery of numerous 
O-GlcNAcylated proteins. In contrast to shotgun MS, a targeted MS method 
would be beneficial when working on a pre-selected protein of interest. Firstly, 
a targeted MS might require lesser labeling and enrichment steps than 
shotgun MS, which would make the sample preparation less time-consuming 
and tedious (e.g. 2 full days are required to complete O-GlcNAc labeling 
through chemical substitution (Zachara et al., 2011)). Secondly, a targeted 
MS approach might be able to directly quantify the amount of native O-
GlcNAcylated peptide, whereas quantification has so far only be reported on 
labeled peptides which can introduce a bias (Wang et al., 2009), (Khidekel 
and Hsieh-Wilson, 2007), (Wells et al., 2002). 
Multiple Reaction Monitoring (MRM) is a targeted MS method used to detect 
and quantify expected peptides of predetermined fragmentation masses 
(Hoffmann, 1996), as described in Figure 5-1. MRM-MS is usually associated 
with a liquid chromatography (LC)-coupled to a triple-quadruple (QQQ) mass 
spectrometer. The first mass analyzer (Q1) filters masses corresponding to 
the expected peptides ions which are then fragmented in the collision 
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chamber (Q2). The resulting fragment ions matching the expected fragment 
masses are searched for in Q3 (Picotti and Aebersold, 2012). MRM-MS 
reports the intensity traces of precursor-fragment ions couples, also called 
transition couples, during LC elution (Picotti and Aebersold, 2012). Transition 
traces originated from the same precursor simultaneously co-elute, therefore 
confirming the existence of the expected peptide.  
 
Figure 5-1 Overview of Multiple Reaction Monitoring MS (MRM-MS) strategy. 
The m/z values of the expected peptide and fragment ions are calculated to draw a list of 
transition couples (top-left). This list of transition couples is used to program the MRM-MS 
machine. The peptides from the sample mixture (potentially containing the expected peptide) 
are separated on nano-LC (liquid chromatography) (top-right). The eluting peptides are then 
ionized and injected on the pre-programmed MRM-MS. The MRM-MS will report the detection 
of the programmed transition couples. After analysis, the presence of the expected peptide will 
be confirmed by the detection of co-eluting expected transition couples (bottom-left).    
 
In addition, the integration of peptide transition traces gives an area value 
which is proportional to the amount of the detected peptide thus enabling LC-
MRM-MS to be used for quantification purposes without the need for peptide 
labeling (Mani et al., 2012). Beside quantification, the other advantage of 
MRM is its ability to detect low amounts of peptides in a complex mixture  
(Lange et al., 2008). For example, MRM-MS was able to detect non-modified 
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represents a 1,000 fold improvement in comparison with shotgun MS 
(Keshishian et al., 2007). In this regard, MRM-MS has been reported as 
suited for the study of post-translational modifications such as oxidation (Held 
et al., 2010), acetylation (Darwanto et al., 2010), ubiquitinylation (Kirkpatrick 
et al., 2006) and phosphorylation (Domanski et al., 2010), (Wolf-Yadlin et al., 
2007). The use of MRM-MS to detect O-GlcNAcylated peptide was previously 
reported (Yuzwa et al., 2011). There, Yuzwa et al. successfully detected an 
O-GlcNAcylated peptide from human TAU protein recombinantly expressed in 
E. coli. However, MRM-MS has yet to be tested on native O-GlcNAcylated 
proteins which are usually present in very low abundance. In addition, there 
has not been any extensive study reporting MRM-MS characteristics applied 
to O-GlcNAc detection, such as fragmentation pattern, method detection limit, 
quantification and purity required to detect native O-GlcNAcylated peptides. 
In this chapter, we developed the experimental procedure of MRM-MS to 
investigate native O-GlcNAcylated peptides. We first demonstrated that 
MRM-MS is able to robustly detect and quantify the amount of a standard O-
GlcNAcylated peptide (5.2.2. Method detection limit and quantification) and 
also showed that O-GlcNAcylated peptide detection by MRM-MS is not 
affected by the presence of a complex peptide mixture. We then applied this 
methodology to characterize GSK-3β, a kinase related to neurodegenerative 
diseases (Schaffer et al., 2008) and cancers.(Luo, 2009), (Grimes and Jope, 
2001). By using MRM-MS, we demonstrated that GSK-3β is bearing O-
GlcNAc modification in human embryonic stem cells (hESC) and were able to 
discover a novel O-GlcNAcylated GSK-3β peptide (bearing 3 potential O-
GlcNAcylation sites) without extensive enrichments (5.3.2. MRM-MS to 
identify GSK-3β O-GlcNAcylated peptide). To the best of our knowledge, this 
is the first report demonstrating that MRM-MS can be used to analyze native 
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O-GlcNAcylated peptides from a complex mixture. Accordingly, we believe 
that MRM-MS could be integrated with existing O-GlcNAc-related analytical 
methodologies for discovery and quantification purposes. Data from this 
chapter have been published in Analytical Chemistry (Maury et al., 2014).  
 
5.2. MRM-MS to detect a standard O-GlcNAcylated CREB peptide 
5.2.1. Fragmentation pattern  
 
We used a commercially available standard O-GlcNAcylated CREB peptide to 
investigate MRM-MS detection using the transition couples values listed in 
the experimental procedure 3.15 MRM programming. As O-GlcNAc is often 
reported to be lost during fragmentation in Q2 (Chalkley and Burlingame, 
2001), we first compared signal intensities between transitions (precursor-
fragment ions) of ions retaining or losing O-GlcNAc. As expected, the 
transition of ions losing O-GlcNAc presented a higher intensity than the 
transition of ions retaining O-GlcNAc (noted with an asterisk on the figure), 
with an intensity difference ranging from 42 to 1,205 folds (Figure 5-2 A). In 
addition, transitions of peptide backbone with O-GlcNAc loss and of O-
GlcNAc oxonium ion were among the most intense transitions, confirming the 
general observation of a loss of O-GlcNAc during the fragmentation in Q2 
(Chalkley and Burlingame, 2001). Even though we are able to detect O-
GlcNAc peptide based on ions retaining O-GlcNAc (Figure 5-2 B), we chose 
to focus on transitions of fragment ions losing O-GlcNAc because it gave 




Figure 5-2 MRM-MS is able to detect standard O-GlcNAcylated CREB peptide. 
A. Comparison of representative LC-MRM-MS traces between transitions of ions retaining 
(noted * in the figure) or losing O-GlcNAc. B. Representative LC-MRM-MS traces from an 
injection of 250 pg of standard O-GlcNAcylated CREB peptide with transitions of +1 charged 
precursor coupled to fragment ions retaining O-GlcNAc modification. C. Representative LC-
MRM-MS traces from an injection of 250 pg of standard O-GlcNAcylated CREB peptide with 
transitions of +1 charged precursor coupled to fragment ions losing O-GlcNAc modification. 







































































































5.2.2. Method detection limit and quantification 
 
In a second step, we determined for the standard O-GlcNAcylated CREB 
peptide, the method detection limit defined as "the minimum concentration of 
a substance that can be measured and reported with 99% confidence” 
(Currie, 1988). Even though as little as 0.5 pg (0.5 fmol) of peptide gave rise 
to a good signal to noise ratio (7,000 folds in average), the transition traces 
were not clearly resolved (Figure 5-3 A, B). Whilst 1 or 2 clear transitions are 
often reported for peptide detection, we used a more stringent threshold of 4 
clear transitions to define the method detection limit. On this basis, 2.5 pg (3 
fmol) was chosen as our method detection limit.  
Furthermore, by integrating all LC-MRM-MS traces, a calibration curve 
(Relative area/peptide amount) was drawn with a 0.996 coefficient of 
determination (Figure 5-3 C). This calibration curve suggests that MRM-MS is 
a robust method to detect and quantify the amount of O-GlcNAcylated peptide 




Figure 5-3 MRM-MS presents a method detection limit of 3 fmol. 
Comparison of representative LC-MRM-MS traces from A. 1000 pg to 250 pg; and B. 2.5 pg to 
0.1 pg of standard O-GlcNAcylated CREB peptide. C. Calibration curve of standard O-
GlcNAcylated CREB peptide with 1000; 750; 250; 100; 50 pg inputs. The area values were 
obtained by integrating LC-MRM-MS traces. Each sample was run in triplicate. The calibration 
curve in presented in panel C. is the mean of the triplicate.      
 
5.2.3. Detection in a complex mixture 
 
We then tested if the detection of O-GlcNAcylated peptide would be affected 
by the presence of a complex mixture. The standard O-GlcNAcylated CREB 
peptide was mixed with trypsin-digested whole cell lysate obtained from 
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pg of O-GlcNAc peptide were respectively investigated in a ratio O-GlcNAc 
peptide: hESC lysate from 5:95 to 1:99. The presence of hESC lysate was 
confirmed by the detection of transition couples values (listed in 3.15 MRM 
programming) corresponding to two ACTIN peptides obtained after a trypsin 
digestion (Figure 5-4).  
 
Figure 5-4 Detection of ACTIN peptides in the complex mixtures (O-GlcNAcylated 
peptide : hESC lysate). 
LC-MRM-MS traces of two ACTIN peptides from mixture of composition 5:95 (O-GlcNAcylated 
peptide : hESC lysate) containing respectively 12.5 pg and 2.5 pg of O-GlcNAcylated peptides 
for each injection. 
 
With a ratio as low as 1:99 (O-GlcNAc peptide: hESC lysate), MRM-MS was 
still able to detect 12.5 pg (Figure 5-5 A) and 2.5 pg (Figure 5-5 B) of the 
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O-GlcNAcylated peptide were clear of non-specific peak during the whole LC 
run (Figure 5-5 C, D). Even though the noise slightly increased with a higher 
ratio of 1:10,000; the O-GlcNAcylated peptide remained clearly detectable by 
MRM-MS (Figure 5-5 E). 
 
Figure 5-5 MRM-MS remains able to detect standard O-GlcNAcylated CREB peptide in a 
complex mixture. 
LC-MRM-MS traces from standard O-GlcNAcylated CREB peptide: hESC lysate mixture in the 
ratios: 5:95; 2.5:97.5 and 1:99 for respectively A. 12.5 pg and B. 2.5 pg of standard O-
GlcNAcylated CREB peptide. LC-MRM-MS traces for the whole 40 min LC run of mixture 1:99 
(O-GlcNAcylated peptide: hESC lysate) containing respectively C. 12.5 pg; and D. 2.5 pg of 
standard O-GlcNAcylated CREB peptide. E. LC-MRM-MS traces for the whole 40 min LC run 
of mixture 1:10,000 (O-GlcNAcylated peptide: hESC lysate) containing 2.5 pg of standard O-
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5.3. MRM-MS to discover a novel O-GlcNAcylated GSK-3β peptide 
5.3.1. GSK-3β O-GlcNAcylation 
 
After completing the proof-of-concept experiments using the standard O-
GlcNAcylated CREB peptide, we focused our attention to employing the 
MRM-MS technology to detect previously unreported native O-GlcNAcylated 
peptides. For this purpose, the glycogen synthase kinase-3 beta (GSK-3β) 
protein was chosen as candidate for two reasons. Firstly, GSK-3β kinase 
activity is related to diseases such as neurodegenerative diseases (Schaffer 
et al., 2008) cancer (Luo, 2009), (Grimes and Jope, 2001), and competes with 
OGT  to modify identical sites on some proteins (Chalkley et al., 2009). 
Secondly, GSK-3β has also been reported to be modified (Lubas and 
Hanover, 2000) and regulated (Shi et al., 2012) by O-GlcNAc modification. To 
date, the O-GlcNAcylation site of GSK-3β is still unknown. 
Therefore, GSK-3β O-GlcNAcylation in hESC was investigated. By using an 
anti-O-GlcNAc antibody to enrich for O-GlcNAcylated proteins in hESC, GSK-
3β was immunoprecipitated (Figure 5-6, IB: Anti-GKS-3 β, lower panel). In 
addition, by treating hESC with PUGNAc to increase global level of O-
GlcNAcylation level (Figure 5-6, IB: Anti-O-GlcNAc, upper panel), the amount 
of precipitated GSK-3β was increased (Figure 5-6, IB: Anti-GKS-3 β, lower 




Figure 5-6 GSK-3β is O-GlcNAcylated in hESC. 
Western and Eastern blots of immunoprecipitated (IP) O-GlcNAcylated proteins from hESC 
treated without (-) or with (+) 100 μM of PUGNAc for 24 h using an anti-O-GlcNAc and an anti-
GSK-3β antibodies. 
 
GSK-3β O-GlcNAc modification sites were predicted based on human GSK-
3β protein sequence (Uniprot accession number: P49841) by using a web-
based bioinformatics resource: the database of O-GlcNAcylated proteins and 
sites (dbOGAP) (Wang et al., 2011). Six O-GlcNAcylation sites were 
predicted on GSK-3β using this tool (Table 5-1).  
 
Table 5-1 List of predicted GSK-3β O-GlcNAcylation sites by the database dbOGAP 
(Wang et al., 2011). 
 
5.3.2. MRM-MS to identify GSK-3β O-GlcNAcylated peptide 
 
The predicted GSK-3β O-GlcNAcylation sites were then investigated by 
MRM-MS. For that, GSK-3β enrichment was kept to a minimum: i.e. only 20 
Input IP











Rank Position Modified amino acid Score
1 235 T 0.1371
2 38 T 0.1228
3 66 S 0.1151
4 35 S 0.1113
5 152 T 0.1109
6 398 S 0.101
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µg of whole hESC lysate were separated through gel electrophoresis. Based 
on the molecular weight of GSK-3β, a gel slice around 45 kDa was excised 
and processed for proteolysis using either trypsin or Glu-C digestions. The 
presence and digestion of GSK-3β was confirmed by the detection of 
transition couples values (listed in 3.15 MRM programming) corresponding to 
the expected non-modified GSK-3β peptides following trypsin (Figure 5-7 A) 
and Glu-C digestions respectively (Figure 5-7 B).  
 
Figure 5-7 Detection of non-modified GSK-3β peptides by MRM-MS. 
LC-MRM-MS traces of GSK-3β peptides by A. trypsin digestion; and B. Glu-C digestion in 
phosphate buffer. 
 
Similarly, taking the transition couples values for the predicted modified 
peptides (in 3.15 MRM programming), we identified by MRM-MS the 
overlapping peptides: VT38TVVATPGQGPDRPQEVSYTDTK+O-GlcNAc from 





































































from Glu-C digestion (Figure 5-8 C, D). The detection of those two 
overlapping peptides not only validates the identification of GSK-3β O-
GlcNAcylated peptides but also helps in narrowing down the potential O-
GlcNAcylation sites to 3 possibilities which are T38, T39 and T43.  
 
Figure 5-8 Detection of native O-GlcNAcylated GSK-3β peptides by MRM-MS. 
LC-MRM-MS traces of O-GlcNAcylated GSK-3β peptides by A. and B. trypsin digestion 
(VTTVVATPGQGPDRPQEVSYTDTK+O-GlcNAc); and C. and D. Glu-C digestion 
(GSKVTTVVATPGQGPD+O-GlcNAc).   
 
Next, we used the identified peptide (GSKVTTVVATPGQGPD + O-GlcNAc) 
to demonstrate the use of MRM for quantifying changes in O-GlcNAcylation, 
between hESC non-treated and treated with PUGNAc (Figure 5-9 A). A non-
modified GSK-3β peptide (YTPTARLTPLE) was used as a MS loading control 
(Figure 5-9 B). By integrating the (GSKVTTVVATPGQGPD + O-GlcNAc) 
peptide trace and normalizing the area value with the one from the non-
modified peptide (YTPTARLTPLE) used as MS loading control, the amount of 
(GSKVTTVVATPGQGPD + O-GlcNAc) peptide was shown to increase by 2.5 
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fold following PUGNAc treatment (Figure 5-9 C). Concordantly, an increase of 
2.6 fold was observed for the overlapping trypsin digested O-GlcNAcylated 
peptide (VTTVVATPGQGPDRPQEVSYTDTK + O-GlcNAc) following 
PUGNAc treatment (Figure 5-9 D, E and F).  
 
Figure 5-9 MRM-MS is able to monitor changes in GSK-3ß O-GlcNAcylation level upon 
PUGNAc treatment. 
Comparison between hESC non-treated (Control) and hESC treated with 100 μM of PUGNAc 
for 24h (+ PUGNAc). Representative LC-MRM-MS traces of A. Glu-C digested O-
GlcNAcylated GSK-3β peptides (GSKVTTVVATPGQGPD+O-GlcNAc); and of B. Glu-C 
digested non-modified GSK-3β peptide (YTPTARLTPLE) used as MS loading control. C. 
Comparison of the area values from the integration of O-GlcNAcylated GSK-3β peptides traces 
normalized by the non-modified GSK-3β peptide. D. Trypsin digested O-GlcNAcylated GSK-3β 
peptide (VTTVVATPGQGPDRPQEVSYTDTK + O-GlcNAc). E. Trypsin digested GSK-3β 
peptide (VIGNGSFGVVYQAK) used as MS loading control. F. Comparison of the area values 
from the integration of (VTTVVATPGQGPDRPQEVSYTDTK + O-GlcNAc) traces normalized 
by (VIGNGSFGVVYQAK) peptide.   
 
In contrast to (GSKVTTVVATPGQGPD + O-GlcNAc), the amount of its 
corresponding non-modified peptide (GSKVTTVVATPGQGPD) normalized by 
(YTPTARLTPLE) was not significantly affected by PUGNAc treatment (Figure 
5-10). This is not surprising since the amount of O-GlcNAcylated peptide 
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might be negligible in comparison to its corresponding non-modified peptide; 
indeed the stoichiometry of O-GlcNAc on specific proteins is usually lower 
than10% (Hart and Akimoto, 2009), (Kim, 2011). 
 
Figure 5-10 PUGNAc treatment doesn’t induce change in GSKVTTVVATPGQGPD peptide 
amount. 
Comparison between hESC non-treated (Control) and hESC treated with PUGNAc. 
Representative LC-MRM-MS traces of A. Glu-C digested GSK-3β peptide 
(GSKVTTVVATPGQGPD); and of B. Glu-C digested GSK-3β peptide (YTPTARLTPLE) used 
as MS loading control. C. Comparison of the area values from the integration of 





In this chapter, we investigated the potential of MRM-MS to detect and 
quantify O-GlcNAcylated peptides. We obtained the following key findings: 
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1. Even though most of O-GlcNAc moiety is lost during fragmentation in 
Q2; MRM-MS is able to detect O-GlcNAcylated peptides by selecting 
precursor ions corresponding to O-GlcNAcylated peptides. 
2. MRM-MS presents a method detection limit of 3 fmol when studying 
the standard O-GlcNAcylated CREB peptide. In addition, this method 
detection limit is not affected by the presence of a complex peptide 
mixture containing a percentage as low as 1 % of the standard O-
GlcNAcylated CREB peptide. 
3. MRM-MS is able to robustly quantify the amount of standard O-
GlcNAcylated CREB peptide. 
4. Native GSK-3β is O-GlcNAcylated in hESC. 
5. MRM-MS is able to detect novel GSK-3β O-GlcNAcylated peptides 
following a simple gel electrophoresis separation without the need for 
additional labeling or enrichment. In addition, MRM-MS is able to 
quantify the increase amount of O-GlcNAcylated peptide following 
PUGNAc treatment. 
We believe that MRM-MS could be integrated with existing O-GlcNAc 
analytical techniques as an early discovery tool to quickly narrow down 
potential O-GlcNAcylation sites on a specific protein. We showed that MRM-
MS is sensitive enough to detect low amounts of O-GlcNAcylated peptide and 
therefore does not require extensive enrichment and labeling. Beside 
qualitative detection, we demonstrated that MRM-MS method can be applied 
to robustly quantify the amount of native O-GlcNAcylated peptides. As O-
GlcNAc research often involves comparing protein O-GlcNAcylation level 
between cell compartments (Sugi et al., 2011), mutant cells (Wang et al., 
2012) drug-treated cells (Kang et al., 2008) and stem cell differentiation (Jang 
et al., 2012); a quantification instrument such as MRM-MS will be beneficial 
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for future O-GlcNAc research. Furthermore, as MRM-MS is also able to 
identify and quantify phosphorylated peptides (Domanski et al., 2010), (Wolf-
Yadlin et al., 2007), MRM can become a powerful tool to investigate the 
interplay between phosphorylation and O-GlcNAcylation. 
In the next chapter (CHAPTER 6), we will make use of the established MRM-
MS methodology to quickly narrow down potential O-GlcNAcylation sites on a 
selected hESC O-GlcNAcylated protein. We will also take advantage of the 
MRM-MS quantification ability to monitor O-GlcNAcylation variation during 
hESC differentiation.  
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CHAPTER 6 - FUNCTIONAL MODULATION OF 




In CHAPTER 4, we demonstrated that O-GlcNAcylation specifically regulates 
hPSC differentiation towards the ectoderm and adipose lineages. Therefore, 
this suggests that some hPSC differentiation pathways are regulated by O-
GlcNAcylated proteins.  
In this chapter, we pursued the functional study of O-GlcNAc in hESC. Using 
a proteomic approach, we first identified hESC O-GlcNAcylated proteins and 
revealed that most of our highest hit proteins are involved in pluripotency 
properties (6.2 Identification of hESC O-GlcNAcylated proteins). We followed 
up by focussing our study on RING2, a PRC1 protein catalysing the 
ubiquitinylation of histone H2AK119 to repress gene expressions (2.8.1 
Polycomb Repressive Complexes). We showed that RING2 is O-
GlcNAcylated at specific sites T250/S251 and S278 (6.4 RING2 O-GlcNAcylation 
sites). We also demonstrated that RING2 O-GlcNAcylation is modulating 
RING2 protein-protein interaction towards CBX7 and RYBP. CBX7 and RYBP 
are two proteins known to be mutually exclusive for RING2 (Tavares et al., 
2012) and to direct RING2 repression towards specific gene subsets 
exclusive for either CBX7 or RYBP (Morey et al., 2013). Moreover, O-GlcNAc 
excess increased RING2-CBX7 affinity and reduced RING2-RYBP affinity 
(6.5 Effect of PUGNAc on RING2). Taken together, our data suggest that O-
GlcNAc modulates the composition of PRC1 and ultimately directs the 
repression of specific gene subsets during hESC differentiation. A manuscript 




6.2. Identification of hESC O-GlcNAcylated proteins 
 
To identify the O-GlcNAcylated proteins in hESC, 3 complementary 
approaches were taken. These include:  
(a). IP identification. hESC O-GlcNAcylated proteins were immunoprecipitated 
with the anti-O-GlcNAc antibody and identified by QTOF MS (Figure 6-1 A). 
Via this approach, a total of 29 proteins were identified.  
(b). Biotin-QTOF identification. Using the click-it chemistry O-GlcNAcylated 
proteins were specifically biotin labeled (as described in Figure 6-1 B). Bona 
fide biotin-labeling was confirmed by the apparition of bands revealed by 
avidin-HRP (Figure 6-1 C). Biotin-labeled proteins were then enriched by 
affinity chromatography using an avidin resin. To discriminate bona fide 
enriched-biotin-labeled proteins from non-specific proteins (non-labeled 
protein enriched by avidin resin); two sets of samples were run side by side 
for mass spectrometry identification: Test sample (labeled and enriched 
proteins) and Control sample (non-labeled and enriched) (Figure 6-1 D). 
Consequently, bands 1 to 24 from the Test lane (Figure 6-1 D) and bands 
from 1* to 24* from the Control lane (in Figure 6-1 D) were excised, 
processed through trypsin proteolysis and identified by QTOF MS. By 
assuming that all peptides have similar ionization, the number of identified 
peptides was considered to correlate to protein abundance. Therefore, 
proteins with a number of identified peptides in the Control lane greater or 
equal to the number of peptides in the Test lane were considered as non-
specific avidin binders and were discarded (a total of 200 proteins were 
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discarded). Using this stringent threshold, a total of 130 proteins were 
identified through Biotin-QTOF identification. 
(c). Biotin-Orbitrap identification. This approach also involved click-it biotin 
labeling however instead of using QTOF for MS identification, the Orbitrap 
MS was utilised for analysis. Indeed, as the Orbitrap mass analyzers use 
differences in m/z (mass on charge ratio) resonance to separate ions 
whereas QTOF relied on ions stability and time of flight (Adam et al., 2001). 
From the same sample, orbitrap and QTOF might therefore detect different 
peptides. In addition, Orbitrap is also known to have 10 times higher 
resolution than QTOF which necessitating a higher processing time might not 
be able to identify as many peptides as QTOF. Overall, Orbitrap was chosen 
as a MS alternative for the last approach to detect a different repertoire and 
possibly with a higher mass accuracy of peptides as compared to QTOF. A 




Figure 6-1 Identification of hESC O-GlcNAcylated proteins using different approaches. 
A. hESC O-GlcNAcylated proteins were immunoprecipitated with an anti-O-GlcNAc antibody. 
The arrowheads are pointed out bands which were cut, processed through trypsin proteolysis 
and finally identified by QTOF mass spectrometry (IP identification). The arrow with tail points 
out the antibody light chain. B. Overview of hESC O-GlcNAcylated proteins process through 
click-it biotin labeling. Briefly, whole hESC lysate was first subject to Gal-T1 enzymatic 
treatment to specifically add a Gal-N3 on O-GlcNAc modification. Then a chemical reaction was 
carried out to biotin-label O-GlcNAc-Gal-N3 modification. The biotin-labeled O-GlcNAcylated 
proteins were enriched through an avidin resin and identified by either QTOF mass 
spectrometry (Biotin-QTOF identification) or Orbitrap mass spectrometry (Biotin-Orbitrap 
identification). C. Coomassie blue staining and Eastern blot of hESC lysate processed through 
Click-iT biotin labeling. Positive control corresponds to O-GlcNAcylated α-crystallin protein. D. 
Coomassie staining of avidin enriched proteins. Bands in the squares were cut, processed 
though proteolysis and identified by mass spectrometry. 24 bands were processed from the 
Test sample (biotin-labeled and enriched) (noted from 1 to 24). As a control, 24 bands from the 
Control sample (non-labeled and enriched) (noted from 1* to 24*) were also processed.     
 
Taking together the 3 approaches, a total of 235 unique proteins were 
identified (the complete protein list can be found in APPENDIX C – List of 
identified hESC O-GlcNAcylated proteins). Cellular localization and biological 
processes of the identified proteins were searched through PANTHER 
classification system (http://www.pantherdb.org/ (Mi et al., 2010)). As 
expected, the identified O-GlcNAcylated proteins were mainly cytoplasmic (68 
% of them) and ribonucleoproteins (26 %) (Figure 6-2 A). The main biological 
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processes found included: metabolic, cellular process and cell cycle 
corresponding respectively to 26 %, 19 % and 9 % of the identified O-
GlcNAcylated proteins (Figure 6-2 B). The finding of metabolism pathways as 
the main modified biological process was not surprising considering the key 
role of O-GlcNAc for nutrient sensing (Caldwell et al., 2010). In addition, 9 % 
of the identified proteins were involved in developmental processes which 
mainly consisted of morphogenesis and ectoderm development. These 
results further support our previous findings from CHAPTER 4 demonstrating 
a specific role of O-GlcNAc in ectoderm differentiation.  
The protein lists from the three different identification approaches (IP, Biotin-
QTOF and Biotin-Orbitrap) were compared side by side using Bioinformatics 
& Evolutionary Genomics webtool 
(http://bioinformatics.psb.ugent.be/webtools/Venn/). From the obtained Venn 
diagram: 2 proteins were found in both the IP and the Biotin-Orbitrap 
identifications; and 24 proteins were common for Biotin-QTOF and Biotin-
Orbitrap identifications (Figure 6-2 C). These 26 proteins found in several 





Figure 6-2 Cellular localization and biological processes of the identified hESC O-
GlcNAcylated proteins. 
A. Cellular localization and B. Biological processes of the 235 unique hESC O-GlcNAcylated 
proteins identified. The protein classification was made using Panther classification system (Mi 
et al., 2010). C. Veen diagram for the three identification approaches (IP; Biotin-QTOF and 
Biotin-Orbitrap). 
 
In the literature, 16 of the ‘highest hit proteins’ from our list were reported to 
be involved in stem cells properties among which 9 are linked to ectoderm 
differentiation and 3 linked to adipose differentiation. Those data further 
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strengthen our findings from CHAPTER 4. In addition, 4 of the ‘highest hit 
proteins’ have previously been reported as O-GlcNAcylated in other cell types 














From top to bottom: the 2 O-GlcNAcylated proteins identified in both IP and Biotin-Orbitrap 
identifications; the 24 O-GlcNAcylated proteins identified in both Biotin-QTOF and Biotin-
Orbitrap identifications; noteworthy O-GlcNAcylated proteins identified in IP, Biotin QTOF and 
Biotin-Orbitrap identifications. On the first page, the proteins are given with their respective 
accession number, name and mass spectrometry results. On the second page, protein 
involvement for stem cell properties (Stem Cells), ectoderm differentiation (Ecto.), adipose 
differentiation (Adip.) is reported with the corresponding literature reference. In addition, 
previous report of protein O-GlcNAcylation is indicated (O-GlcNAc).  
 
6.3. Confirmation of protein O-GlcNAcylation  
 
To validate the reliability of our hESC O-GlcNAcylated protein identification, 
immunoprecipitation experiments were carried out on two of the identified 
proteins: hnRNP K and HP1γ (Table 6-1). 
HP1γ is a heterochromatin-associated protein involved in gene repression 
and differentiation. Overexpression of HP1γ gene has been shown to promote 
embryonal carcinoma cells differentiation into all three germ layers (Morikawa 
et al., 2013). Reciprocally, Hp1γ silencing improved the reprogramming of 
mouse embryonic fibroblast into iPSC (Sridharan et al., 2013).  
hnRNP K is a RNA-binding protein involved in both transcription activation 
and transcription silencing (Choi et al., 2009a). In addition, hnRNP K has 
been shown to regulate neuronal differentiation in mouse neuroblastoma 
(Yano et al., 2005) and rat pheochromocytoma (Cao et al., 2012). hnRNP K 
was also shown to repress erythroid differentiation in human leukemia cells 
(Naarmann-de Vries et al., 2013).  
In addition to hnRNP K and HP1γ, we also investigated the O-GlcNAcylation 
of RING2. As previously described (2.8.2 PcG and pluripotency), RING2 is an 
important regulator of development and stem cell differentiation. Interestingly, 
RING2 is also known to repress PAX6 and MSX1 genes (Morey et al., 2013), 
(Stock et al., 2007). PAX6 and MSX1 were used as ectoderm markers in 
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CHAPTER 4 and were both down-regulated during hPSC differentiation after 
increasing O-GlcNAcylation level.  
In our experiments, hnRNP K, HP1γ and RING2 were all detected after the 
immunoprecipitation of O-GlcNAcylated proteins (Figure 6-3 A). In addition, a 
higher amount of those proteins was pulled down following cell treatment with 
PUGNAc, which is consistent with those proteins being O-GlcNAcylated 
(Figure 6-3 A). Reciprocally, following RING2 immunoprecipitation, RING2 
band was detected with the anti-O-GlcNAc antibody (Figure 6-3 B). The same 
was obtained for hnRNP K (Figure 6-3 C) and HP1γ (Figure 6-3 D).  
 
Figure 6-3 RING2, hnRNP K and HP1γ are O-GlcNAcylated in hESC. 
Western and Eastern blots analyses of immunoprecipitated (IP) A. O-GlcNAcylated proteins; B. 
RING2; C. hnRNP K and D. HP1γ proteins from hESC treated without (-) or with (+) 100 μM of 
PUGNAc for 24 h. For D; Input and IP solutions were run in non-reducing conditions as in 
reducing condition HP1γ and antibody light chain co-elute and are difficult to distinguish. Of 
note, HP1γ apparent molecular weight is changed from 25kDa (in reducing condition) to 40kDa 




6.4. RING2 O-GlcNAcylation sites 
 
We decided to further investigate RING2 O-GlcNAcylation and more precisely 
localize RING2 O-GlcNAcylation sites.  
We first made use of the MRM-MS strategy developed in CHAPTER 5. 
RING2 O-GlcNAc modification sites were predicted based on human RING2 
protein sequence (Uniprot accession number: Q99496) using the database of 
O-GlcNAcylated proteins and sites (dbOGAP) (Wang et al., 2011). Five O-
GlcNAcylation sites were predicted on RING2 based on the prediction tool 
(Table 6-2) and subsequently investigated by MRM-MS.  
 
Table 6-2 List of predicted RING2 O-GlcNAcylation sites by the database dbOGAP (Wang 
et al., 2011). 
 
Similarly to the experiment described in CHAPTER 5 (5.3.2. MRM-MS to 
identify GSK-3β O-GlcNAcylated peptide), RING2 enrichment was kept to a 
minimum hence only 20µg of whole hESC lysate was separated through gel 
electrophoresis; and based on the expected molecular weight of RING2, a gel 
slice around 40 kDa was excised and processed through proteolysis. By 
taking the transition couples values for the predicted modified peptides (see 
3.15 MRM programming), we identified by MRM-MS the O-GlcNAcylated 
RING2 peptide T250SGNATVDHLSK +O-GlcNAc (Figure 6-4 A). Furthermore, 
an increase of 2 fold in RING2 O-GlcNAcylated peptide (TSGNATVDHLSK 
+O-GlcNAc) was observed following cell treatment with PUGNAc (Figure 6-4 
B, C and D). 
Rank Position Modified amino acid Score
1 250 T 13.793
2 251 S 13.186
3 96 S 9.286
4 200 S 8.935




Figure 6-4 Detection of an O-GlcNAcylated RING2 peptide by MRM-MS. 
A. Representative LC-MRM-MS trace of O-GlcNAcylated RING2 peptide (TSGNATVDHLSK 
+O-GlcNAc). Comparison between hESC non-treated (Control) and hESC treated with 100 μM 
of PUGNAc for 24h (+ PUGNAc) of LC-MRM-MS traces for B. O-GlcNAcylated RING2 peptide 
(TSGNATVDHLSK +O-GlcNAc); and C. α-enolase peptide (VNQIGSVTESLQACK) used as 
loading control. D. Comparison of the area values from the integration of (TSGNATVDHLSK 
+O-GlcNAc) traces normalized by the area value measured for (VNQIGSVTESLQACK) 
peptide.   
 
In order to pinpoint RING2 O-GlcNAcylation site, we made use of the strategy 
described in Figure 6-5 A. For this purpose, RING2 was immunoprecipitated, 
trypsin digested, and subjected to the BEMAD reaction (β-elimination-Michael 
addition). BEMAD was used to substitute O-GlcNAc by DTT (as described in 
Figure 2-10) in order to stabilize the post-translational modification for MS 
analysis. DTT-modified peptides were enriched with thiopropyl sepharose 6B 
column and identified by Orbitrap MS. Two RING2 DTT-modified peptides 









































































































































O-GlcNAcylated in Figure 6-4); and GE[S278-DTT]NQMNLDTASEK (Figure 
6-5 B and C). Even though [(T250S251)-OGlcNAc]GNATVDHLSK peptide was 
identified with a spectrum containing most of the y ions, the obtained 
spectrum doesn’t allow to pinpoint precisely the DTT modification between 
either T250 or S251.  
 
Figure 6-5 RING2 is O-GlcNAcylated at S250 or T251. RING2 is also O-GlcNAcylated at S278. 
A. Overview of RING2 treatments before mass spectrometry analysis. Briefly, 
immunoprecipitated RING2 protein was digested and subject to phosphatase treatment to 
remove phosphate groups. Then the peptides were subject to BEMAD reaction in order to 
substitute O-GlcNAc group by DTT (as described in Figure 2-10 Scheme representing the β-
elimination-Michael addition (BEMAD) performed on O-GlcNAcylated proteins). Finally the 
DTT-modified peptides were enriched on thiopropyl sepharose and analyzed by MS.  B. and C. 
MS2 analysis of RING2 DTT-modified peptides [(TS)-OGlcNAc]GNATVDHLSK  and GE[S-




To further validate these results, we recombinantly expressed mutated 
versions of HA-tagged RING2 in hESC. Following immunoprecipitation of the 
recombinant HA-RING2 with an anti-HA antibody, we analysed the effect of 
the mutations on the O-GlcNAcylation of HA-RING2. The mutation of S278 
residue into an alanine residue (noted S278A) did not seem to affect 
significantely HA-RING2 O-GlcNAcylation (Figure 6-6 A) which implies a low 
stoichiometry of S278 O-GlcNAcylation. Additionnally, in contrast to [(T250S251)-
OGlcNAc]GNATVDHLSK, we were not able to detect GE[S278-O-
GlcNAc]NQMNLDTASEK from native RING2 by MRM-MS (data not shown) 
which further suggests a low stoichiometry of S278 O-GlcNAcylation. However, 
the simple mutations of T250 (noted T250A), S251 (noted S251A) as well as the 
double mutation T250 and S251 (noted TASA) into alanine all reduced HA-
RING2 O-GlcNAcylation (Figure 6-6 B). Those data suggest that both T250 




Figure 6-6 RING2 T250 or S251 residues are necessary for the protein O-GlcNAcylation. 
A. Western and Eastern blots analyses of hESC transfected with Empty plasmid used as a 
control, HA-RING2 (noted RING2) and a mutated HA-RING2 where S278 residue was 
substituted by an alanine residue (noted S287A). B. Western and Eastern blots analyses of 
hESC transfected with Empty plasmid, HA-RING2 (noted RING2), mutated version of HA-
RING2 at residue T250 (noted T250A), residue S251 (noted S251A) and the double mutant 
(noted TASA). Arrowheads point out the recombinantly expressed HA-RING2 proteins whereas 
arrows with tail point out the native RING2 protein.  
 
We concluded that RING2 possesses at least one occupied O-GlcNAcylation 
site at either T250 or S251 in hESC. Interestingly, this O-GlcNAcylation site 
appears in a region of RING2 (from I248 to P324) previously reported as 
mediating the exclusive binding to CBX7 and RYBP (Bezsonova et al., 2009), 
(Wang et al., 2010a). Due to the high sequence similarity with CBX7, all 
RING2-binding CBX proteins (CBX2, 4, 6 and 8) were also hypothesized to 
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result, we hypothesized that RING2 O-GlcNAcylation could regulate RING2 
interaction with RYBP and RING2-binding CBX proteins (CBX2, 4, 6, 7 and 
8). 
 
6.5. Effect of PUGNAc on RING2 functions 
 
Before testing the effect of O-GlcNAcylation on RING2 protein-protein 
interaction, we first compared the protein expression of RING2, RYBP and 
the different CBX proteins during hESC differentiation.  
Similarly to what was reported in mESC (Morey et al., 2012); RING2 protein 
expression slightly decreased during hESC differentiation (Figure 6-7 A). This 
protein expression decrease was also confirmed by MRM-MS monitoring of 
the non-modified RING2 peptide (LALEELR) and normalizing its amount by 
GAPDH peptide (GALQNIIPASTGAAK) used as a LC-MS loading control 
(Figure 6-7 C, D, F). Interestingly, the percentage of RING2 O-GlcNAcylation 
on TSGNATVDHLSK also decreased during hESC differentiation, as shown 
by monitoring the amount of (TSGNATVDHLSK + O-GlcNAc) normalized by 
the non-modified RING2 peptide (LALEELR) and by GAPDH peptide 
(GALQNIIPASTGAAK) (Figure 6-7 B, E). These data suggest that RING2 O-
GlcNAcylation on TSGNATVDHLSK might be functionaly important during 
hESC differentiation. 
Besides RING2, expression of CBX2 and RYBP protein both decreased 
during hESC differentiation (Figure 6-7 A). CBX7 protein expression did not 
significantly change during differentiation (Figure 6-7 A). In contrast, CBX4, 6 
and 8 protein expressions all increased following differentiation (Figure 6-7 
A). Therefore, we decided to investigate in hESC the effect of O-
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GlcNAcylation on RING2 affinity for RYBP, CBX2 and CBX7; as these 
proteins are strongly expressed in hESC and potentially interact together.  
Following RING2 immunoprecipitation, CBX2 protein was not detected from 
the immunoprecipitation product (data not shown). However, CBX7 and 
RYBP proteins were both detected in the RING2 immunoprecipitation product 
(Figure 6-7 G). Interestingly, O-GlcNAc excess following PUGNAc treatment 
increased RING2-CBX7 affinity and decreased RING2-RYBP affinity (Figure 
6-7 G). These data suggest that O-GlcNAc modulates RING2 affinity towards 




Figure 6-7 O-GlcNAcylation is regulating RING2-RYBP and RING2-CBX7 affinities. 
A. Western blot analyses in hESC and hESC embryoid bodies at day 4, 7, 14, 21 post-
differentiation. Representative LC-MRM-MS traces from hESC and hESC embryoid bodies at 
day 4, 7, 14, 21 of B. O-GlcNAcylated RING2 peptide (TSGNATVDHLSK +O-GlcNAc); C. 
RING2 peptide (LALEELR); and D. GAPDH peptide (GALQNIIPASTGAAK) used as loading 
control. E. Comparison of the area values from the integration of (TSGNATVDHLSK +O-
GlcNAc) LC traces normalized by the area values of the LC traces corresponding respectively 
to LALEELR and GALQNIIPASTGAAK peptides. F. Comparison of the area values from the 
integration of LALEELR LC traces normalized by the one from GALQNIIPASTGAAK peptide. 
G. Western blots analyses of RING2 immunoprecipitation product (IP) from hESC treated 
without (-) or with (+) 100 μM of PUGNAc for 24 h. The arrowhead points at CBX7 band. The 
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In this chapter, we investigated the functional modulation of RING2 by O-
GlcNAc. We obtained the following key findings: 
1. Two hundred and thirty five unique hESC O-GlcNAcylated proteins 
were identified using a series of glycoproteomic approaches. The 
majority of the ‘highest hits proteins’ are known to be involved in stem 
cell properties.  
2. RING2 is O-GlcNAcylated in hESC with at least one occupied O-
GlcNAcylation sites at T250 or S251. This O-GlcNAcylation decreases 
during hESC spontaneous differentiation.  
3. O-GlcNAcylation is regulating RING2 affinity towards CBX7 and 
RYBP. O-GlcNAc excess increases RING2-CBX7 affinity and reduces 
RING2-RYBP affinity. 
In conclusion, our data suggest that by regulating RING2 protein-protein 
interaction, O-GlcNAc might direct RING2 repression towards specific gene 
subset. Interestingly, as RING2 O-GlcNAcylation decrease during hESC 
differentiation; our data suggest that RING2 protein-protein affinity might 
change during differentiation (decreasing affinity for CBX7 and increasing 
affinity for RYBP). This mechanism might be used during differentiation to de-
repress CBX7-targerted genes which have been reported as controlling 
differentiation and development (Morey et al., 2012). The same mechanim 
might also promote the repression of RYBP-targeted genes which were 
shown to control cell cycle (Morey et al., 2012). Overall, this hypothetical 
mechanism might be necessary during differentiation to 1) slow down cell 
growth, and 2) direct stem cell differentiation.  
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CHAPTER 7 -  CONCLUSIONS AND 
RECOMMENDATIONS  
 
This thesis focused on O-GlcNAcylation in two main aspects: a functional 
study aspect and a technology development aspect. The functional study 
aspect aimed to investigate the overall importance of O-GlcNAcylation for 
hPSC properties (CHAPTER 4); and then study the specific functions of O-
GlcNAc on a targeted protein: RING2 (CHAPTER 6). In parallel, the 
technology development aspect aimed to develop MRM-MS experimental 
procedure to facilitate the discovery and quantification of native O-
GlcNAcylated proteins (CHAPTER 5).  
In this chapter, we summarized the main findings of this thesis and provided 
recommendations for future investigations.  
 
7.1     O-GlcNAc level / O-GlcNAc enzymes and pluripotency 
 
In CHAPTER 4, we showed that O-GlcNAcylation level remained relatively 
constant during hPSC differentiation. In contrast to mESC where excess of O-
GlcNAc increased pluripotency (Jang et al., 2012); here we reported that 
increasing O-GlcNAcylation level neither affected the maintenance of hESC 
pluripotency nor the loss of pluripotency during hPSC differentiation. Our data 
seem to indicate that further increase in O-GlcNAc level is not important for 
hPSC pluripotency. However, the expression of both OGT and OGA 
decreased during hPSC differentiation, suggesting that a high level of both 
OGT and OGA might be important for the maintenance of pluripotency. 
Maintaining such a high expression of both OGT and OGA may allow 
pluripotent cells a high dynamic for rapid addition and removal of O-GlcNAc 
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on specific proteins, thereby fine-tuning the level of O-GlcNAc modified-
proteins involved in regulating pluripotency and self-renewal. This O-GlcNAc 
dynamism might be very important for dynamical processes such as cell cycle  
which have previously been reported as regulated by O-GlcNAcylation 
(Dehennaut et al., 2007), (Tan et al., 2013).  
It will therefore be interesting to further study the relation between O-GlcNAc 
dynamism and pluripotency. To do so, one could simultaneously knock-down 
OGT and OGA genes in hPSC, to monitor the effect on 1) cell viability; 2) cell 
proliferation; 3) hPSC pluripotency maintenance; and 4) pluripotency loss 
during hPSC differentiation. Following the double knock-down, a decrease in 
pluripotency and/or cell proliferation might be observed. Alternative to knock-
down, one could attempt to simultaneously overexpress OGT and OGA in 
hPSC and observe the effect of such overexpression. 
 
7.2     O-GlcNAc level and O-GlcNAc enzymes feedback loop 
 
In CHAPTER 4, we also demonstrated that increasing O-GlcNAcylation level 
increased OGA and decreased OGT expression in differentiating hESC. The 
opposite trend was previously reported in the human liver carcinoma cells 
(HepG2), where a decrease in the substrate UDP-GlcNAc increased OGT 
mRNA expression within 3 h (Taylor et al., 2009). Our data suggest the 
existence of a feedback loop based on OGA expression and potentially OGT 
expression to balance O-GlcNAc excess in differentiating hESC and probably 
other cell types. Such feedback loops have already been described between 
kinases and phosphorylation to control kinase activity (Roskoski, 2005), 
(Ferrell, 2002). Mechanistically, the feedback loop between O-GlcNAc and O-
GlcNAc enzymes might rely on one or several of the following: 1) histone 
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deacetylase which associates with OGT (Yang et al., 2002); 2) the proposed 
histone acetyltransferase domain of OGA (Vocadlo, 2012); 3) O-
GlcNAcylation of histones (Sakabe et al., 2010); and 4) O-GlcNAcylated 
proteins such as RNA polymerase II, transcription factors and epigenetic tools 
(Ranuncolo et al., 2012).  
A very interestingly, but also challenging, future investigation would be to 
unravel this feedback loop mechanism. We would first recommend to verify 
the existence of this feedback loop in other cell types such as human 
embryonic kidney 293T cells (HEK 293T) or IMR-90. These cell lines are 
useful because they are easier to culture and scale up as compared to hESC 
and may serve as a model system for this work.   
Another strategy could use softwares, such as MotifMap 
(http://motifmap.ics.uci.edu/) (Daily et al., 2011), to predict potential 
transcription factors binding to OGT and OGA genes promoters. Following 
this prediction, a ChIP experiment could be carried out to enrich DNA 
sequence bound to the predicted transcription factors and check for 
enrichment of OGT or OGA gene promoters. As preliminary search, we used 
MotifMap with default parameters to identify transcription factor binding motifs 
spanning from 1kbp upstream to 1kbp downstream of OGT and OGA genes. 
This work revealed several potential transcription factors for OGT (GABPα, 
NRF1 and NKX2.5) and OGA (STAT3, STAT6, HNF4, TEF1 and NEUROD1). 
Interestingly enough, some of those predicted transcription factors are known 
to be O-GlcNAc modified like NEUROD1 (Andrali et al., 2007), STAT6 
(Gewinner, 2003), STAT3 (Hahne et al., 2012) and NKX2.5 (Kim et al., 2012).  
Alternatively, a more straightforward approach could make use of a reverse 
ChIP method called Proteomics of Isolated Chromatin segments (PICh; 
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(Déjardin and Kingston, 2009)). Indeed, PICh relies on a specific DNA probe 
to hybridize and pulled down specific chromatin. Then, protein-bound 
chromatin can be identified by MS. PICh could also be used to directly identify 
proteins binding to OGT and OGA promoters as well as to test if the histones 
of OGT and OGA promoters are O-GlcNAcylated. 
 
7.3     O-GlcNAcylation level and differentiation 
 
In CHAPTER 4, we also revealed that O-GlcNAc excess modulated hPSC 
differentiation towards specific lineages. 
Increasing O-GlcNAcylation level was able to enhance hPSC differentiation 
towards adipose-related mesoderm lineage. Our data extends to human a 
previous report showing that O-GlcNAcylation level increases during murine 
adipocyte differentiation (Ishihara et al., 2010). In addition, PPAR γ and 
C/EBP α, adipose-related transcription factors, were previously reported to be 
modified and controlled by O-GlcNAc in mouse cells (Ji et al., 2011), (Li et al., 
2009). As we showed that O-GlcNAc controls PPAR γ and C/EBP α mRNA 
expressions, we infer that genes upstream of PPAR γ and C/EBP α may also 
be regulated by O-GlcNAc. O-GlcNAcylation effect on adipose differentiation 
might be explained by the fact that O-GlcNAc is used as glucose level sensor 
by cells (Issad and Kuo, 2008). Therefore by up-regulating O-GlcNAc level, 
stem cells could sense high glucose availability and respond by increasing 
differentiation towards adipose.  
Apart from adipose commitment, hPSC ectoderm differentiation was inhibited 
upon up-regulation of O-GlcNAcylation level. In agreement with our results, 
increasing O-GlcNAcylation level was reported to impair chicken axon 
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branching  and mouse neuroepithelial cell number and growth (Yanagisawa 
and Yu, 2009). In this paper, the authors suggested that the decrease in 
neuroepithelial cell number could be attributed to the activation of cell death 
signalling through O-GlcNAc modification (Yanagisawa and Yu, 2009). 
However, based on our results, the link between O-GlcNAc and cell death 
might be more complex in hPSC. Indeed, by increasing O-GlcNAcylation, 
hPSC differentiations towards some lineages were unaffected and adipose 
lineage was even promoted. In addition, in our feeding experiments using 
OGA inhibitors such as PUGNAc and Thiamet G, we did not observe any 
significant effect on hPSC cell viability (data not shown). Therefore, our data 
suggest that O-GlcNAc might not be directly linked to hPSC EB cell death or 
that this link is stronger towards the ectoderm lineage.   
Our data in human PSC differ from Jang H. et al.‘s results in mouse PSC 
(Jang et al., 2012). In this particular publication, the authors showed that a 
high level of O-GlcNAcylation maintains mESC pluripotency state and inhibits 
differentiation for all germ layers. Our results suggest a more complex 
function for O-GlcNAcylation in human PSC. Similar to mESC, we showed 
that in hPSC, high level of O-GlcNAcylation inhibits differentiation towards 
ectoderm. However, in contrast to mESC; O-GlcNAc does not appear to 
affect visceral-related endoderm and cardiac-related mesoderm differentiation 
in hPSC. Moreover, high level of O-GlcNAcylation increases hPSC 
differentiation towards adipose-related mesoderm. Whereas high level of O-
GlcNAcylation enhances mESC pluripotency; excess of O-GlcNAcylation 
does not significantly affect the expression of pluripotent markers in hESC. 
Overall, the comparison between Jang H. et al’s results and our results 




A future recommendation would consist of monitoring the effect of global O-
GlcNAcylation decrease on hPSC differentiation. To do so, we would not 
recommend using Alloxan, X1 or DON; as in our hands those inhibitors did 
not produce any significant decrease in global O-GlcNAcylation level in hESC 
or EB (data not shown). Instead, we would recommend knocking-down OGT 
or overexpressing OGA to decrease global O-GlcNAcylation level in hPSC. 
As excess of O-GlcNAc specifically enhanced hPSC differentiation towards 
adipose lineage, our results might be relevant for the development of hPSC 
differentiation protocols and commercial applications. Indeed, a current 
strategy for hPSC applications consists of expanding hPSC and differentiating 
them towards mesenchymal stem cells (MSC) (Hematti, 2011). Those hPSC 
derived MSC could become a well-characterized and homogenous cell 
source for diverse applications such as cancer treatment (Bak et al., 2011), 
drug screening (Cressey, 2012) and regenerative medicine (Karlssson et al., 
2009). hPSC derived adipose MSC in particular, hold a great potential for 
regenerative medicine because of their ability to differentiate towards various 
cell lines such as hepatocytes (Aurich et al., 2009), pancreatic endocrine 
(Silva et al., 2012), osteoblasts (Mihaila et al., 2012) and cardiomyocytes 
(Chang et al., 2012). Such strategies could rely on O-GlcNAc upregulation 
(through the use of OGA inhibitors or OGT protein transfection) as a 
temporary and genetic modification-free method to increase the amount of 
hPSC-derived adipose MSC.  
 
7.4     Function of RING2 O-GlcNAcylation 
 
In CHAPTER 6, we showed that RING2 is O-GlcNAcylated in hESC. Our data 
complements previous reports showing that other polycomb proteins are O-
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GlcNAcylated like HPH (Gambetta et al., 2009), (Chalkley et al., 2009);  and 
YY1 (Hiromura et al., 2003), (Hiromura et al., 2003).   
In addition, we also demonstrated that O-GlcNAcylation regulated protein-
protein interaction for RING2-CBX7 and RING2-RYBP. O-GlcNAc excess 
increased RING2-CBX7 affinity, and inversely decreased RING2-RYBP 
affinity. RYBP and CBX7 were shown to exclusively bind to RING2 (Tavares 
et al., 2012) to direct RING2 repression towards specific gene subsets (Morey 
et al., 2013). Indeed, CBX7 was shown to target genes mainly involved in 
development and differentiation; whereas RYBP was shown to target genes 
mainly involved in cell cycle and metabolic processes (Morey et al., 2013). 
Therefore, our data suggest that O-GlcNAc excess might favour the 
repression of genes targeted by CBX7 and allows the expression of genes 
targeted by RYBP. Such mechanisms could be used by the cell machinery as 
a switch to either promote stem cell expansion or trigger differentiation as 
detailed in Figure 7-1. Furthermore, as RING2 O-GlcNAcylation decrease 
during hESC differentiation we can hypothesize that during differentiation 
RING2 affinity is decreased for CBX7 and increased for RYBP. This 
hypothetical mechanism could be used by the cell machinery to de-repress 
CBX7-targeted genes which are known to control differentiation and 
development (Morey et al., 2012).  
Overall, our data suggest that by regulating RING2 protein-protein interaction, 
O-GlcNAc might direct RING2 repression towards specific gene subsets to 




Figure 7-1 Hypothetical model of hESC regulation by RING2 O-GlcNAcylation. 
 
A future planned experiment will consist of monitoring the effect of RING2 O-
GlcNAcylation on RING2-DNA binding by ChIP-sequencing as described in 
Figure 7-2. Besides gene identification, the experiment will also be used to 
analyse the effect of RING2 O-GlcNAcylation on RING2 binding to 
CBX7/RYBP; and on H2A ubiquitinylation of chromatin bound by RING2.    
 
Figure 7-2 Overview of the planned ChIP experiment. 
Briefly, HA-RING2 will transiently be expressed in hESC. Following cross-linking, lysis and 
sonication, anti-HA agarose will be used to enrich complexes binding to HA-RING2. In the 
figure, we hypothesize that O-GlcNAcylated HA-RING2 will bind to CBX7 and non-O-
GlcNAcylated HA-RING2 will bind to RYBP. Then, WGA lectin agarose will be used to separate 
non-O-GlcNAcylated HA-RING2 complexes (flow-through fraction) and O-GlcNAcylated HA-
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link and be analysed. We will then analyse the effect of HA-RING2 O-GlcNAcylation on 1) 
RYBP/CBX7 binding by Western blot; 2) H2A ubiquitinylation of the chromatin bound by HA-
RING2 by Eastern blot; and 3) HA-RING2-DNA binding by ChIP-sequencing.  
 
 
Furthermore, we proposed to investigate the consequence of mutating 
endogenous RING2 O-GlcNAcylation sites on differentiation and 
development. Considering the difficulty in mutating endogenous genes in 
hESC we would therefore recommend using mESC which are easier to 
manipulate and mutate by homologous recombination (Maury et al., 2011). 
Fortunately polycomb proteins are well conserved in mammals; a comparison 
between murine RING2 (Uniprot accession number: Q9CQJ4) and human 
RING2 (Uniprot accession number: Q99496) revealed a difference of only a 
single amino acid residue (on a total of 336). This disparate amino acid, 
located at the 214th position, is changing a methionine in human to a valine 
residue in mouse. As the found human RING2 O-GlcNAcylation sites (T250, 
S251 and S278) are quite distant from this 214th residue, we might expect a 
conservation of the O-GlcNAcylation sites as well as O-GlcNAcylation 
functions between human RING2 and murine RING2.  To perform this future 
investigation, we would first advice to confirm mouse RING2 O-GlcNAcylation 
sites and functions using similar approaches and strategies as in CHAPTER 6 
starting from mESC. If RING2 O-GlcNAcylation sites and functions are 
conserved, the next step would consist of mutating endogenous RING2 O-
GlcNAcylation sites in mESC. Such mutant mESC line could then be used to 
study the effect of RING2 mutation on 1) mESC spontaneous differentiation; 
similarly to CHAPTER 4; and 2) PRC1-mediated gene repression using ChIP 
sequencing and microarray. If those experiments give significant phenotype, 
one could envisage the creation of a transgenic mouse (Cho et al., 2009); to 
study the effect of RING2 O-GlcNAcylation on mouse embryogenesis and 




7.5     Improving MRM-MS for O-GlcNAc study 
 
In CHAPTER 5, we showed that MRM-MS can be used as a qualitative 
method for the detection of native O-GlcNAcylated protein. Unfortunately, 
most of O-GlcNAc moiety is not stable and lost during fragmentation in Q2, 
which is in accordance with previous reports done with shotgun MS (Chalkley 
and Burlingame, 2001), (Hahne et al., 2012). As fragment ions retaining O-
GlcNAc might not be distinguishable from background noises, MRM method 
might not be ideal to directly pinpoint the exact O-GlcNAc modification site on 
a peptide. Nonetheless, as the method was able to specifically select 
precursor ions corresponding to O-GlcNAcylated peptides and detect their 
corresponding transitions, MRM-MS is able to detect O-GlcNAcylated 
peptides. We also reported a method detection limit of 3 fmol for the standard 
O-GlcNAcylated CREB peptide. This method detection limit was not affected 
by the presence of a complex peptide mixture with a percentage as low as 1 
% for the O-GlcNAcylated peptide. In comparison, O-GlcNAc stoichiometry 
has been reported to vary from 100 % to as low as 2 % (Rexach et al., 2010). 
Therefore, our data support that MRM-MS could be used to identify O-
GlcNAcylated peptide from biologically samples where O-GlcNAc peptides 
only represent a small percentage of the total mixture. Furthermore, by using 
this method, we discovered a novel O-GlcNAcylated GSK-3β peptide 
following a simple gel electrophoresis separation without any need for 
additional labeling or enrichment. As a result, MRM-MS doesn’t require as 
extensive labeling or enrichment steps as the ones often reported for shotgun 
MS, (Vosseller et al., 2006), (Wang et al., 2010b), (Zachara et al., 2011). In 
this regard, MRM-MS should be integrated with existing O-GlcNAc analytical 
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techniques as an early discovery tool to quickly narrow down potential O-
GlcNAcylation sites on a specific protein.  
Beside qualitative detection, we also demonstrated that MRM-MS method can 
be applied to robustly quantify the amount of native O-GlcNAcylated peptides 
without the need for labeling. As O-GlcNAc research often involves 
comparing protein O-GlcNAcylation level between cell compartments (Sugi et 
al., 2011), mutant cells (Wang et al., 2012), drug-treated cells (Kang et al., 
2008) and stem cell differentiation (Jang et al., 2012), (Maury et al., 2013); a 
quantification method such as MRM-MS will be beneficial for future 
researches related to O-GlcNAc. Furthermore, as MRM-MS is also able to 
identify and quantify phosphorylated peptides (Domanski et al., 2010), (Wolf-
Yadlin et al., 2007), MRM-MS can become a powerful tool to investigate the 
interplay between phosphorylation and O-GlcNAcylation.   
In CHAPTER 5, we also reported GSK-3β O-GlcNAcylation in hESC. This 
modification might regulate GSK-3β kinase function in hESC as reported 
previously in HEK 293T cells (Shi et al., 2012). In addition, we narrowed down 
the potential O-GlcNAc modification sites to three specific threonine residues: 
T38, T39 and T43. Interestingly, a phosphorylation site on an adjacent serine 
(S25) was previously reported (Oppermann et al., 2009); suggesting that there 
might be interplay between phosphorylation and O-GlcNAcylation on GSK-3β. 
Furthermore, MRM-MS identified O-GlcNAcylated sites could be used to 
predict O-GlcNAc function. For example, the domain of the GSK-3β O-
GlcNAcylated site identified in our study was previously reported to be 
involved in a GSK-3β kinase auto-inhibition mechanism (Dajani et al., 2001). 
Hence, we hypothesize that in hESC GSK-3β O-GlcNAcylation may be 
involved in a similar mechanism.  
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Future investigation might be undertaken to first pinpoint GSK-3β O-
GlcNAcylation site and then confirm the function of GSK-3β O-GlcNAcylation; 
similarly to the functional study carried out on RING2 protein in CHAPTER 6. 
Another potential recommendation might be to try to improve the MRM-MS 
method to enable more precise localization of O-GlcNAc modification sites on 
the peptide. Indeed, reports from Hart’s group have shown the advantage of 
the BEMAD reaction to substitute O-GlcNAc by DTT which in contrast to O-
GlcNAc, is stable through fragmentation (Zachara et al., 2011), (Vosseller et 
al., 2005). Therefore, we envisage that by coupling the BEMAD reaction with 
the MRM-MS method would help to pinpoint the precise location of the O-
GlcNAc on the protein through the detection of the DTT substitution sites. 
Alternatively, using a mass spectrometer equipped with electron transfer 
dissociation (ETD) fragmentation might also enable the MRM-MS method to 
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QTOF Biotin- Orbitrap 






















QTOF Biotin- Orbitrap 
P63208 S-phase kinase-associated protein 1 (Cyclin-A/CDK2-associated protein p19) SKP1 EMC19 OCP2 SKP1A TCEB1L 18.1 17 1 4.4    Q13435 Splicing factor 3B subunit 2 (Pre-mRNA-splicing factor SF3b 145 kDa subunit) SF3B2 SAP145 100.2 115 2 2.0    B3KUK2 Superoxide dismutase  (EC 1.15.1.1) SOD2 19.7 20 3 16.5   P17987 T-complex  protein 1 subunit alpha (TCP-1-alpha) (CCT-alpha) TCP1 CCT1 CCTA 60.3 60 2 5.4    P50991 T-complex  protein 1 subunit delta (TCP-1-delta) (CCT-delta) CCT4 CCTD SRB 54.7 115 1 2.2    P49368 T-complex  protein 1 subunit gamma ( CCT3 CCTG TRIC5 56.4 60 2 4.9    Q5SZX9 T-complex  protein 1 subunit gamma (Fragment) CCT3 17.5 75 1 6.2    P30048 Thioredoxin-dependent peroxide reductase,  mitochondrial PRDX3 AOP1 27.7 17 1 2.7    Q8IUR0 Trafficking  protein particle complex subunit 5 TRAPPC5 20.8 20 1 6.9    P37837 Transaldolase (EC 2.2.1.2) TALDO1 TAL TALDO TALDOR 37.5 60 2 5.0    Q53GC9 Transgelin  variant (Fragment)  20.9 20 13 48.4   Q53GC9 Transgelin  variant (Fragment)  20.9 27 3 15.8   P37802 Transgelin-2 (Epididymis tissue protein Li 7e) (SM22-alpha homolog) TAGLN2 KIAA0120  CDABP0035 22.4 20 2 13.1   B3KRM8 Translin, isoform CRA_b TSN hCG_37642 20.9 25 1 7.2    P60174 Triosephosphate isomerase  (TIM) TPI1 TPI 26.7 25 12 51.4   P60174 Triosephosphate isomerase  (TIM) (EC 5.3.1.1) TPI1 TPI 17.9 30 1 7.2    Q8WU19 TUBA1B protein TUBA1B 37.2 125 5 19.7   Q8N532 TUBA1C protein TUBA1C 36.6 20 3 9.5    Q96B85 TUBB protein (Fragment) TUBB 30.3 40 5 21.4   Q53GA7 Tubulin alpha 6 variant (Fragment)  49.8 40 6 16.3   A4UCT2 Tubulin beta 2C (Fragment)  10.0 50 2 23.9   Q5CAQ5 Tumor rejection  antigen (Gp96) 1 TRA1 92.3 80 12 16.3   Q5CAQ5 Tumor rejection  antigen (Gp96) 1 TRA1 92.3 115 2 2.5    Q59FC6 Tumor rejection  antigen (Gp96) 1 variant (Fragment)  65.9 75 3 7.3    P68036 Ubiquitin-conjugating enzyme E2 L3 UBE2L3 UBCE7 UBCH7 14.1 17 1 7.4    P61088 Ubiquitin-conjugating enzyme E2 N UBE2N BLU 17.1 12 1 7.2    P61088 Ubiquitin-conjugating enzyme E2 N (EC 6.3.2.19) UBE2N BLU 17.1 20 1 7.2    Q13404 Ubiquitin-conjugating enzyme E2 variant 1 UBE2V1 CROC1 UBE2V UEV1 P/OKcl.19 11.8 12 1 11.4   Q15819 Ubiquitin-conjugating enzyme E2 variant 2 (DDVit 1) UBE2V2 MMS2 UEV2 16.4 23 1 8.3    A0AVP6 UTS2 protein UTS2 11.0 70 1 8.5    Q9HAP0 Valosin-containing protein (Fragment) VCP 33.7 80 1 4.3    Q9HAP1 Valosin-containing protein (Fragment) VCP 34.4 125 1 3.3    Q6FH24 VBP1 protein (von Hippel-Lindau binding protein 1, isoform CRA_a) VBP1 hCG_17616 18.7 28 1 7.5    Q96IF9 VCP protein (Fragment) VCP 71.0 110 1 2.0    O95292 Vesicle-associated membrane  protein-associated protein B/C (VAMP-B/VAMP-C) VAPB UNQ484/PRO983 27.2 30 2 8.2    B0YJC4 Vimentin  (Vimentin  variant 3) VIM 49.6 55 8 15.8   P18206 Vinculin (Metavinculin) (MV) VCL 123.7 125 16 15.8   A2A3S1 Voltage-dependent anion-selective channel protein 2 (Fragment) VDAC2 12.0 75 1 7.3    P13010 X-ray repair cross-complementing protein 5 (EC 3.6.4.-) (86 kDa subunit of Ku antigen) XRCC5 G22P2 82.7 80 5 8.1    Q1KSF8 XTP3TPA-transactivated protein 1 XTP3TPATP1 23.6 60 2 10.6   Q6PKI6 YBX1 protein (Fragment) YBX1 29.4 40 4 21.8   Q6PKI6 YBX1 protein (Fragment) YBX1 29.4 47 2 12.8   B4DQX7 Zyxin (Zyxin, isoform CRA_a) (cDNA FLJ53163,  highly similar to Zyxin) ZYX hCG_96060 45.0 75 1 2.9     
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